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Abstract 
Gene delivery is an important tool used in the study and manipulation of human 
pluripotent stem cells for regenerative medicine purposes. However current methods of 
transient gene delivery are still highly inefficient. Using materials and biologically based 
concepts, I aim to develop new methods and protocols to enhance the efficiency of gene 
delivery. For the materials aspect,  diblock copolymers consisting of poly(ethylene glycol)-
block-poly(γ-4-(((2-(piperidin-1-yl)ethyl)amino)methyl)benzyl-L-glutamate) (PEG-b-
PVBLG-8) were synthesized and evaluated for their ability to mediate gene delivery in 
hard-to-transfect cells, such as IMR-90 human fetal lung fibroblasts and human embryonic 
stem cells (hESCs). The PEG-b-PVBLG-8 contained a membrane-disruptive, cationic, 
helical polypeptide block (PVBLG-8) for complexing with DNA and a hydrophilic PEG 
block to improve the biocompatibility of the gene delivery vehicle. PEG-b-PVBLG-8 
diblock polymers with a high degree of polymerization have a greater transfection 
efficiency and lower toxicity in IMR-90 cells than the commercial reagent Lipofectamine 
2000. The usefulness of PEG-b-PVBLG-8 was further demonstrated via the successful 
transfection of hESCs without a measured loss in cell pluripotency markers. This system 
proved to be inefficient for hESCs, thus I designed a system that uses the combination of 
a cell specific and materials approach. Plasmid DNA was condensed with PVBLG-8 to 
form nanocomplexes, which were further coated with hyaluronic acid. PVBLG-8 has 
proven to be an effective gene delivery material in certain cell lines, due to its membrane 
disruptive properties. Yet in more sensitive cell lines, like hESCs, it proves to be toxic and 
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thus ineffective. Hyaluronic acid not only shields the positive charges from the helical 
peptides, but also acts as a targeting moiety for cell surface receptor CD44, which binds 
and facilitates the internalization of hyaluronan for degradation. Despite the negative 
charged surface, the gene transfection of the cells increased by 1.5 fold with reduced 
toxicity. I demonstrated that the increased transfection efficiency is due to the CD44 
mediated targeting delivery of DNA by HA coating nanocomplex. In addition, this 
nanocomplex system can be further activated through the endosomal specific degradation 
of HA by hyaluronidase to expose PVBLG-8. From the biological aspect, a small molecule 
that selectively inhibits the Rho-associated kinase inhibitor (Y-27632) was discovered to 
transiently alter the hESC morphology to induce spreading and reduced membrane tension. 
These morphological changes allowed the increase of plasmid transfection, siRNA 
transfection and nanoparticle uptake to increase substantially. Cells were also able to 
recover after treatment back to normal pluripotent stem cell morphology and express 
important pluripotency markers. These new methods expands the field of gene delivery in 
human pluripotent stem cells, which can be further applied to other biomedical 
applications. 
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CHAPTER 1 
Introduction and Background 
Human embryonic stem cells (hESCs) hold tremendous potential in the field of 
regeneration due in particular to two characteristics: pluripotency and self-renewal. The 
former allows these cells to differentiate into either the endoderm, mesoderm or ectoderm 
lineages and therefore can transform into virtually any of the cells found in the human 
body. The latter allows the cells to proliferate almost endlessly. This is unlike many of the 
other cells in the human body, which are limited in their growth and expansion. This has 
been a major hindrance in regenerative medicine thus far. In order for research in the lab 
to be an applicable technique for biomedical purposes, it is necessary to obtain enough of 
a certain type of cell in order to encapsulate it into three-dimensional scaffold for tissue 
engineering uses. This second main property of embryonic stem cells solves this issue of 
the source of the cells and allows one to grow a large quantity of the cells. The ability of 
human pluripotent stem cells to differentiate into virtually any cell in the body is a double 
edged- sword, where although it holds much promise, the control of the differentiation is a 
major hurdle to be solved. Once accurate control is held over pluripotency as well as 
growth, tissue engineering could hold much promise.  
 
Despite the tremendous potential in the application of tissue engineering, there are 
still many caveats and ethical issues in the use of embryonic stem cells. Embryonic stem 
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cells are derived from embryos discarded during in-vitro fertilization. Upon entry into the 
blastocyst, the invasive procedure destroys the embryo and thus leads to the biggest ethical 
issue pertaining to human embryonic stem cells; many people believe that the destruction 
of an embryo is considered murder. Another problem that one faces with human embryonic 
stem cells is its direct clinical application, although not of ethical nature. Since these cells 
were not derived from the patient himself, the actual transplantation of the cell as well as 
its differentiated lineages could lead to many immunological complications. For example, 
due to an immunological incompatibility, the patient could contract what is known as graft-
versus-host disease, (GVHD), where the implanted cells are rejected and fail to be grafted 
in the body.  
 
There are various roads to pluripotency, the most obvious is when the sperm is 
reprogrammed by the egg upon normal fertilization resulting in a totipotent cell that gives 
rise to the entire embryo proper and to the extra-embryonic tissues. This is the process that 
nature takes and is associated with near perfect efficiency of reprogramming. For somatic 
cells however, this uphill ascent has classically been achieved by one of two means. For 
Instance, one can introduce nuclei of somatic cells into oocytes. In this process, typically 
only 5% of cloned embryos develop to term. Nevertheless one can get surviving off-spring, 
as in the remarkable case of Dolly the sheep. Alternatively, one can do a simple cell fusion 
of somatic cells to ES cells, but the resultant cells, although multipotent by various 
criterion, have tetraploid nuclei. In both scenarios, the oocytes/ES cells provide undefined 
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trans-acting factors that actively remodel the somatic genome back to a pluripotent state. 
While the former process is saddled by serious ethical and technical concerns, the latter 
process of cell fusion results in the formation of tetraploid cells, which have limited clinical 
potential. What would be ideal is an in vitro reprogramming approach where simple 
expression of few factors could directly convert somatic cells into pluripotent stem cells. 
Until recently this had been merely fantasy. Now, the two main problems in using 
embryonic stem cells can also be easily overcome with in-vitro reprogrammed induced 
pluripotent stem cells. These cells have been found to look and behave like human 
embryonic stem cells in all forms.  
 
Viral Gene Delivery  
Both viral and non-viral gene delivery have been explored extensively for basic 
research as well as therapeutic applications. In the pursuit of regenerative medicine, gene 
delivery is an important tool to manipulate and control cell fate. One of the newest 
applications of gene delivery is the reprogramming of terminally differentiated cells into 
induced pluripotent stem cells (iPSCs) or, more recently, induced neurons, blood 
progenitors and cardiomyocytes [3-5]. In the pioneering work of Yu et al., a recombinant 
lentivirus carrying the genes for OCT4, SOX2, NANOG and LIN28 was used to reprogram 
IMR-90 fetal lung fibroblasts into iPSCs [6]. While the resulting iPSCs were 
characteristically and functionally pluripotent, they nonetheless retained remnants of viral 
DNA as a result of lentiviral integration. This could have serious implications if tissue 
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derived from such iPSCs was used therapeutically. Non-viral approaches to achieve safe, 
virus-free reprogramming of IMR-90 cells using synthetic polymers and lipids have been 
fruitless as existing gene delivery materials have proven to be inefficient at mediating 
effective gene delivery in these cells.  
 
The genetic manipulation of hESCs is also an important tool in regenerative 
medicine. The control and overexpression of specific genes afforded by gene delivery is 
valuable not only in efforts to control stem cell fate, but also to study cell behavior in 
differentiation and gene targeting studies [7]. Lentiviral transduction has been established 
as an effective method for gene delivery to hESCs because of their consistently high 
transfection efficiency and capability to maintain stable transgene expression[8].  
 
Viral gene delivery is typically more efficient than its non-viral counterpart but 
poses increased risks of immunogenicity, insertional mutagenesis, and viral integration into 
the host genome [9]. While the integration event results in permanent transgene 
expression—which may not be desirable for all applications—it also provides a route for 
the prolonged expression of undesired viral components in host cells. As non-viral gene 
delivery relies on synthetic polymers or lipids and DNA that are explicitly free from viral 
components, it is generally considered a safer alternative than viral gene therapy. 
Therefore, there is a push to develop non-viral gene delivery materials to match the 
efficiency of viral vectors [10-19]. 
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Non-Viral Gene Delivery 
Non-viral gene delivery, often characterized by its desired biocompatibility and 
minimal immunogenicity, provides an ideal alternative to viral gene delivery [10-13,16-
24]. Nevertheless, non-viral systems applied to human embryonic stem cell colonies are 
hindered by low transfection efficiency, which limits their applications [22,24-26]. There 
have been several materials developed for non-viral gene delivery into a variety of cells, 
such as poly-beta amino esters [25] and cationic helical peptides, like PVBLG-8 [27,28], 
but very few are effective in hESCs. But, there are many issues that plague non-viral gene 
delivery in hESCs, such as low efficiency and high cytotoxicity. Due to the physiology of 
hESCs, non-viral gene delivery nanoparticles have low uptake efficiency. After the 
nanoparticles are taken up, the DNA/plasmid needs to reach the nucleus for transcription, 
but can be trapped in the endosomes and thus tagged for degradation. Active targeting of 
various cell surface receptors has been found to be quite effective for nanoparticle uptake, 
due to receptor mediated endocytosis. After the nanoparticles are endocytosed, they need 
to quickly escape the endosome and release their DNA cargo. Therefore, it will be very 
practical to develop a smart delivery system with active targeting motif coated on the 
complex, which can enhance the uptake of the gene delivery vehicles and shield the 
cationic polymers to reduce cytotoxicity, and also can quickly escape from the endosome 
after rapid deshelling of the charge shielding moiety in the endosome.   
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 Polypeptides were among the first set of materials examined as non-viral gene 
delivery agents [29-31]. Given the simplicity in synthesis and formulation with anionic 
DNA, cationic poly(L-Lysine) (PLL) was one of the most intensively studied gene delivery 
polypeptides. However, as a DNA delivery vector, unmodified PLL suffered from low 
transfection efficiency. Even following modification with functional moieties like 
saccharide [32,33], imidazole [34], and guanidinium groups [35], PLL has proven to be a 
largely ineffective gene delivery vector. Nonetheless, there have been numerous attempts 
to create novel gene delivery vehicles with modified polypeptides, like 
poly(glycoamidoamine)s [36] and HPMA-oligolysines [37].  
 
 Many biologically active peptides share facially amphipathic helical domains as a 
common structural motif [38,39]. Peptides that possess this structure are often able to 
interact with and destabilize the lipid bilayers of cell membranes. In terms of gene delivery, 
cell membrane destabilization can facilitate cell internalization and escape from endocytic 
vesicles [40,41]. PLL and modified PLL, however, adopt random coil structures because 
strong intramolecular side-chain charge repulsion prohibits α-helix formation. As such, 
PLL functions as a conventional polyelectrolyte in gene delivery studies and exhibits 
limited membrane activity.  
 
Cell Morphology 
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Low transfection efficiency can be largely attributed to the distinct physiology of 
hESCs. hESCs are mildly intrinsically stiff in structure due to the fact that they grow in 
tight colonies and in rounded up shapes [42]. Because of such tight two-dimensional 
colonies, cells in the center are often compressed by the surrounding cells [43] and 
exposure of centered cells to exogenous materials is greatly limited, which prevents 
effective internalization of gene delivery materials and thus leads to low transfection 
efficiency. Such cases have been widely noted in previous gene delivery studies by [24] 
and [44-46], which demonstrates that the outer edge of the hESCs have notably higher 
uptake efficiency. These physical properties of the hESC colony growth pose a large 
limitation in gene delivery that may not be able to be solved through the material design of 
the delivery vector. To this end, I am seeking alternative strategies to increase the gene 
delivery efficiency by manipulating the cellular state and physiology of hESCs.  
 
It has been discovered that pluripotent stem cells have two main states, naïve and 
primed states [1]. Mouse embryonic stem cells (mESC) derived from the inner cell mass 
of developing blastocysts are capable of indefinite maintenance in the pluripotent state. 
These mESCs are termed naïve cells, in which they are capable of chimeric embryo 
contribution. There is another type of pluripotent cell lineage that is derived from 
postimplantation epiblast of mouse embryos termed epiblast stem cells (mEpiSCs), which 
are distinct molecularly and epigenetically from mESCs. These mEpiSCs are incapable of 
chimeric contribution, but able to generate teratomas, demonstrating their pluripotent 
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potential, thus termed primed cells. Naïve cells and primed cells demonstrate tremendous 
difference in their growth condition and morphology. Naïve mESCs depend on LIF/Stat3 
signaling and grow in a packed dome colony, while primed mEpiSCs depend on bFGF and 
TGFb/Activin signaling and grow in a flattened 2D morphology. In addition, it has been 
found that in contrast to naïve mESCs, primed EpiSCs are intolerant to single cell 
passaging. Gene delivery into naïve ESCs have been found to be highly efficient in contrast 
to the primed EpiSCs. It is possible for the primed mEpiSCs to revert back to the naïve 
mESC state with specific overexpression and growth factor treatments. It has been shown 
that human pluripotent stem cells, both hESCs and hiPSCs behave identically to the primed 
mEpiSCs. In a recent report, it was demonstrated that naïve human embryonic stem cells 
could be rewired to behave like mESCs through gene over expression and controlled 
growth factors. In addition, they were able to produce naïve human induced pluripotent 
stem cells [2]. There have been supplemental studies to further efficiently convert the 
primed hESCs to naïve hESCs for more effective therapeutic applications due to their 
robustness and ease of manipulation. Currently, the process is complex and inefficient.  
 
Scope and Organization 
The aim of my PhD research is to develop a new and more effective gene delivery 
system for hESCs through both a materials approach and a more biologically cell based 
approach to control cell fate. In the following four chapters, I will describe unique methods 
developed to overcome obstacles of non-viral gene delivery systems based on the cationic 
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helical peptide, PVBLG-8, and the small molecule Y-27632. The organization of my thesis 
is briefly described below. Chapter 2 describes the chemical modification of PVBLG-8 
with PEG to reduce cytotoxicity from the charges. By establishing that reduced charges 
can reduce cytotoxicity, and still have some gene transfection efficiency, Chapter 3 
discusses other non-chemical modifications of the PVBLG-8 system to retain the low 
cytotoxicity while increasing the transfection efficiency. Acknowledging the importance 
of the physiological state of hESC colonies, Chapter 4 explores coupling a biological 
approach to increasing transfection efficiency, through the transient alteration of the cells 
with Y-27632.  
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Chapter 2 
 
Development of biocompatible, cationic, helical 
polypeptide for non-viral gene delivery to stem cells 
 
 
Significant portions of this chapter were published as “Cationic, helical polypeptide-based 
gene delivery for IMR-90 fibroblasts and human embryonic stem cell" Jonathan Yen, 
Yanfeng Zhang, Nathan Grabrielson, Lichen Yin, Linna Guan, Isthier Chaudhury, Hua Lu, 
Fei Wang, and Jianjun Cheng, Biomaterials Science, 2013, 1, 719 - 727. 
 
2.1 Introduction 
Viral transfections have proven to be quite effective in gene transfection, but none 
of the traditional polymeric gene delivery methods have proven quite as effective in hESCs. 
Therefore a new class of gene transfection material is required for hESCs. Recently, we 
reported a new cationic polypeptide possessing a pH-, ionic- and temperature-stable 
cationic helical structure [1]. Traditionally, charged polypeptides adopt random coil 
orientations because strong intramolecular side-chain charge repulsion prohibits α-helix 
formation. In our reported polypeptide, termed PVBLGn-8 where n is the degree of 
polymerization, the helical structure is stabilized by increasing the distance between the 
charged side chain groups and the polypeptide backbone. This has the net effect of both 
minimizing the effect of charge repulsion while simultaneously stabilizing the helix 
through hydrophobic interaction between the pendent side chain groups. 
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 Our prior characterization of PVBLGn-8 peptides as non-viral gene delivery 
materials revealed that the helical structure facilitates strong, disruptive interactions with 
cell membranes which aid the endosomal escape of the endocytosed complexes of 
polypeptide and DNA [2]. Although gene delivery with PVBLGn-8 proved to be effective 
in COS-7 and HEK 293 cells with comparable performance to the commercial transfection 
agent Lipofectamine 2000 [2], it was largely ineffective in IMR-90 fibroblasts and hESCs 
due to its substantial toxicity in these cells. However, I believe that the cationic helicity of 
PVBLG-8 is an important characteristic that can increase transfection efficiency into hard 
to transfect cells, though it is also responsible for the cytotoxicity in the cells. Therefore, 
before the material can be effectively used in IMR90s and hESCs, the charges need to be 
effectively reduced, while still maintaining some of the cationic helical structure. Thus, I 
have designed and synthesized a diblock copolymer incorporating polyethylene glycol 
(PEG) to the PVBLGn-8 polypeptide. I demonstrated that the addition of PEG to PVBLGn-
8 markedly decreases the toxicity of PVBLGn-8 yet preserves the biological activity and 
gene delivery efficiency of the polypeptide. Moreover, with its reduced toxicity, PEG-b-
PVBLG-8 is able to effectively transfect IMR-90 fibroblasts and human embryonic stem 
cells (Scheme 2.1), which suggests that it may be possible to ultimately achieve higher-
reprogramming efficiency of fibroblasts with a safer non-viral vector.    
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2.2 Materials and Methods 
2.2.1 General 
 All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used 
as received unless otherwise specified. Anhydrous dimethylformamide (DMF) was dried 
by a column packed with 4Å molecular sieves and stored in a glovebox. Tetrahydrofuran 
(THF) and hexane were dried by a column packed with alumina and stored in a glove box. 
OptiMEM and Lipofectamine 2000 were purchased from Invitrogen (Carlsbad, CA, USA). 
pEGFP-N1 was obtained from Elim Biopharmaceuticals (Hayward, CA, USA). The human 
embryonic stem cell line H1 was cultured in mTeSR 1 medium from Stem Cell 
Technologies (Vancouver, Canada). Milli-Mark™ Anti-SSEA-4-PE were purchased from 
EMD Millipore (Billerica, MA, USA). IMR-90 fetal lung fibroblast cells were purchased 
from ATCC (Manassas, VA, USA) and cultured in MEM containing Earle’s balanced salt 
solution supplemented with 10% fetal bovine serum. L-glutamic acid copper(II) complex 
copper(II) salt tetrahydrate[3] and -(4-vinylbenzyl)-L-glutamate N-carboxyanhydride 
(VB-Glu-NCA)[1,4] were prepared by following previously reported procedures. 
 
2.2.2 Instrumentation  
 NMR spectra were recorded on a Varian UI400 MHz, a UI500NB MHz or a VXR-
500 MHz spectrometer. Tandem gel permeation chromatography (GPC) experiments were 
performed on a system equipped with an isocratic pump (Model 1100, Agilent Technology, 
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Santa Clara, CA, USA), a DAWN HELEOS 18-angle laser light scattering detector (also 
known as multi-angle laser light scattering (MALLS) detector, Wyatt Technology, Santa 
Barbara, CA, USA) and an Optilab rEX refractive index detector (Wyatt Technology, Santa 
Barbara, CA, USA). The detection wavelength of HELEOS was set at 658 nm. Separations 
were performed using serially connected size exclusion columns (100, 500, 103 and 104 Å 
Phenogel columns, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA, USA) at 60 °C using 
DMF containing 0.1 M LiBr as the mobile phase. The MALLS detector was calibrated 
using pure toluene with no need for external polymer standards and was used for the 
determination of the absolute molecular weights. The molecular weights (MWs) of all 
polymers were determined based on the dn/dc value of each sample, calculated offline by 
using the internal calibration processed by the ASTRA V software (version 5.1.7.3, Wyatt 
Technology, Santa Barbara, CA, USA). Infrared spectra were recorded on a Perkin Elmer 
100 serial FTIR spectrophotometer equipped with universal attenuated total reflectance 
(ATR), which enabled the analysis of polymer samples in powder form. Circular dichroism 
(CD) measurements were carried out on a JASCO J-700 or a JASCO J-720 CD 
Spectrometer. Ozone was produced by an OZV-8S ozone generator manufactured by 
Ozone Solutions Inc. (Hull, IA, USA). Lyophilization was performed on a FreeZone 
lyophilizer (Labconco, Kansas City, MO, USA). Flow cytometry analysis was conducted 
on a BD FACSCanto 6 color flow cytometry analyzer (Becton Dickinson, Franklin Lakes, 
NJ, USA). Cells were visualized with a Zeiss Axiovert 40 CFL fluorescence microscope 
equipped with a 20 objective (Thornwood, NY, USA). Zeta potential and particle size 
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were analyzed with a Malvern Zetasizer (Worcestershire, UK).  
 
2.2.3 General procedure for the polymerization of VB-Glu-NCA 
 Following previously established procedure to synthesize and polymerize NCAs to 
prepare polypeptides [5-8]. In a glove box, VB-Glu-NCA (56 mg, 0.2 mmol) was dissolved 
in DMF (1 mL) followed by the addition of PEG-amine and 1,5,7-triazabicyclo[4.4.0]dec-
5-ene (TBD) at various monomer:amine:TBD ratios (Table 2.1). The polymerization 
solutions were stirred at room temperature for 24-60 h until VB-Glu-NCA was consumed. 
Aliquots of the polymerization solutions were diluted to 10 mg polymer/mL using DMF 
containing 0.1 M LiBr and analyzed by GPC. The real-time concentration of NCA was 
quantified by measuring the intensity of the anhydride band at 1784 cm-1 by FTIR. The 
conversion of VB-Glu-NCA was determined by comparing the VB-Glu-NCA 
concentration in the polymerization solution versus the initial VB-Glu-NCA concentration. 
When the polymerization was complete, the majority of the DMF was removed under 
vacuum and the polymer was precipitated with ether (15 mL). The resulting PEG-b-
PVBLG polymer was sonicated in ether for 5 min and centrifuged to remove remaining 
solvent. After the sonication-centrifugation steps were repeated two more times, PEG-b-
PVBLG was collected and dried under vacuum (44 mg and 75% yield, and 35 mg and 68% 
yield for PEG113-b-PVBLG76 and PEG113-b-PVBLG287, respectively). 
1H NMR (TFA-d, 
500 MHz):  7.53 (d, 2H, J =7.0 Hz, ArH), 7.39 (d, 2H, J =7.0 Hz, ArH), 6.84 (dd, 1H, J1 
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=11.0 Hz, J2 =18.0 Hz C6H4CH=CH2), 5.91 (d, 1H, J =18.0 Hz, C6H4CH=CH2), 5.43 (d, 
1H, J =11.0 Hz, C6H4CH=CH2), 5.26 (m, 2H, ArCH2), 4.80 (m, 1H, CHCH2CH2COOCH2), 
4.13 (m, -OCH2CH2- in PEG), 2.68 (m, 2H, CHCH2CH2COO), 2.30 (m, 1H, 
CHCH2CH2COO), 2.12 (m, 1H, CHCH2CH2COO).   
 
2.2.4 General procedure for the synthesis of poly(ethylene glycol)-block-poly(γ-(4-
aldehydebenzyl)-L-glutamate) (PEG-b-PABLG)   
 PEG-b-PVBLG (40 mg) was dissolved in chloroform (30 mL) at -78oC. Oxygen 
was then bubbled into the solution for 1 min followed by the bubbling of ozone until the 
solution became blue. The ozone was then replaced by oxygen, which was bubbled into 
the solution for 2 min until the solution became colorless. The solution was degassed and 
back filled with nitrogen. Dimethyl sulfide (1 mL) was then added and the solution was 
stirred at room temperature overnight. Afterwards, the solvent was removed under vacuum 
and the resulting PEG113-b-PABLG76 was purified by sonicating the polymer in methanol 
(3 × 15 mL) and collected by centrifugation. PEG113-b-PABLG76 was dried under vacuum 
(33 mg, 82% yield). PEG113-b-PABLG287 was synthesized from PEG113-b-PVBLG287 by 
following the similar procedure for synthesis of PEG113-b-PABLG76 with 86% yield. 
1H 
NMR (TFA-d, 500 MHz):  10.31 (1H, CHOC6H4), 8.40 (d, 2H, J =7.0 Hz, ArH), 7.96 (d, 
2H, J =7.0 Hz, ArH), 5.71 (2H, CHOC6H4CH2), 5.21 (1H, CHCH2CH2CO2CH2), 4.10 (m, 
-OCH2CH2- in PEG), 3.12 (2H, CHCH2CH2), 2.75 (1H, CHCH2CH2), 2.56 (1H, 
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CHCH2CH2).  
 
2.2.5 General procedure for the preparation of PEG-b-PVBLG-8   
 PEG-b-PABLG (20 mg), N-(2-aminoethyl)piperidine (5 molar equiv relative to the 
Glu repeating unit of PEG-b-PABLG) and borane-pyridine complex (5 molar equiv) were 
mixed in DMF (3 mL) and stirred at 50oC for 48 h (Table 2). The mixture was poured into 
3 M HCl (3 mL) and dialyzed against water for 48 h. The resulting PEG-b-PVBLG-8 was 
lyophilized. The yields of PEG-b-PVBLG-8 copolymers were between 60 and 70%, with 
grafting efficiencies greater than 95%, which was determined as previously reported [2].   
 
2.2.6 General procedure for the analysis of polypeptide conformations by circular 
dichroism (CD)  
 Circular dichroism studies were performed on JASCO J-700 and J-720 CD 
spectrometers. Samples were prepared at polymer concentrations of 0.01-0.1 mg/mL 
unless otherwise specified. In a representative experiment, the sample solution was placed 
in a quartz cell with a path length of 0.5 cm and the mean residue molar ellipticity of the 
polymer was calculated based on the measured apparent ellipticity according to the 
equation: Ellipticity ([θ] in deg·cm2·dmol-1) = (millidegrees × mean residue weight)/(path 
length in millimeters × concentration of polypeptide in mg·mL-1) [9]. For helix-
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temperature dependency studies, the temperature of the sample chamber containing the 
quartz cell was varied from 4 to 70oC using a water bath. A minimum of 10 min was 
allowed for sample temperature equilibration prior to collecting CD measurements. The α-
helix contents of the polypeptides were calculated using the following equation: % α-helix 
= (-[]222 + 3000)/39,000 [10]. 
 
2.2.7 Agarose gel retardation  
 A solution of DNA (0.5 µg) was prepared in OptiMEM (50 µL). Separately, a 
solution of polypeptide in OptiMEM (50 µL) was prepared to achieve the desired 
polypeptide:DNA weight ratio. Following mixing of the two solutions, complexes were 
incubated at room temperature for 20 min, after which an aliquot (20 µL) was withdrawn 
and loading dye (4 µL) was added. The mixture was then run on a 2% agarose gel (100 V, 
60 min). DNA was stained with ethidium bromide and visualized on a Gel Doc imaging 
system (Biorad, Hercules, CA, USA)  
 
2.2.8 Characterization of polymer/DNA complex with zeta potential and dynamic light 
scattering 
Solutions of DNA (25 µg) were prepared in OptiMEM (400 µL).  Separately, a 
solution of polypeptide (1 mg) was prepared in OptiMEM (400 µL). A solution of 
Lipofectamine 2000 (50 µL, 1 mg/mL) in OptiMEM (400 µL) was also prepared as a 
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control. The DNA solution was then mixed with either the polypeptide or Lipofectamine 
2000 solution and allowed to incubate at rt for 20 min.  The size and surface charge of the 
resulting polyplexes were analyzed by dynamic light scattering (DLS) and zeta potential. 
 
2.2.9 Transfection of IMR-90 with Lipofectamine 2000 and PVBLG-8 Polymers 
IMR-90 cells were seeded at 50,000 cells per well in 24-well plates one day prior 
to transfection. On the day of transfection, plasmid pEGFP-N1 DNA (1 μL, 1 mg/mL) was 
diluted with OptiMEM (50 μL). Separately, Lipofectamine 2000 (2 μL, 1 mg/μL) or the 
polymer solution (10-80 µL, 1 mg/mL) was diluted with OptiMEM (50 μL). The individual 
solutions were then mixed gently and allowed to incubate for 5 min at rt, after which they 
were combined and allowed to incubate at rt for another 20 min. The cell media was then 
aspirated and replaced with pre-warmed (37°C) OptiMEM (500 μL). The complex solution 
was added dropwise to the cells. The cells were then incubated at 37°C with 5% CO2 for 4 
h, after which the cell media was replaced with normal culture media (500 μL). After 
incubation for a total of 48 h at 37°C with 5% CO2, the cells were imaged with a fluorescent 
microscopy.  The EGFP transfection efficiency was quantified by flow cytometry.  
 
2.2.10 Sample preparation and flow cytometry analysis 
Prior to analysis by flow cytometry, transfected cells on the 24-well plate were 
washed with 1 PBS (500 μL for each well) to remove any residual serum, dead cells and 
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debris. Next, trypsin (100 µL) was added and incubated for 5-10 min to detach the cells 
from the plate. PBS (100 µL) was then added and pipetted up and down to break up cell 
clumps. A solution of 4% paraformaldehyde (100 µL) was added to fix the cells. Samples 
were kept in covered flow cytometry tubes until analysis (BD FACSCanto, Franklin Lakes, 
NJ, USA). 
 
2.2.11 MTT assay of polymers 
 For MTT assays, 10,000 cells were seeded in each well of a 96-well plate one day 
before transfection. The cells were then transfected as described above, save for an 80% 
reduction in volume and reagent quantity to accommodate the reduced well volume. The 
cells were incubated for 4 h at 37°C in the transfection mix before being returned to fresh 
growth media. After 48 h, the cells were washed with PBS and MTT solution was added. 
Following 4-h incubation at 37°C, MTT solubilization solution (10% Triton X-100 in 
acidic (0.1M HCl) isopropanol) was added to the cells and the absorbance of 570 nm light 
was quantified on a Perkins Elmer plate reader (Waltham, MA, USA). 
 
2.2.12 hESC transfection 
 hESCs were seeded in Matrigel-coated 24-well plates. Plasmid DNA (1 µL, 
1mg/mL) was diluted in OptiMEM (50 µL). The polymer solution (10-40 µL, 1 mg/mL) 
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was diluted with OptiMEM (50 µL). The two solutions were then vortexed gently and 
allowed to incubate for 5 min at rt, after which they were combined and allowed to incubate 
for another 20 min at rt. Next, the mixtures were added to the cells dropwise and allowed 
to incubate at 37°C for 4 h. The media was then aspirated and fresh media was added. After 
48 h, the cells were stained with DAPI (250 µL, 3 nM) and SSEA-4 –PE (250 µL, 0.02 
mg/mL), a pluripotency cell marker, for 30 min at 37 °C.  
 
2.3 Results 
2.3.1 Synthesis and characterization of PEG-b-PVBLG-8 (PEV)  
 -(4-Vinylbenzyl)-L-glutamate N-carboxyanhydride (VB-Glu-NCA) was prepared 
by following previously reported methods [1,2,4]. The ring-opening polymerization of VB-
Glu-NCA with PEG-amine as the macroinitiator yielded PEG-block-poly(-(4-
vinylbenzyl)-L-glutamate) (PEG-b-PVBLG) with controlled molecular weights (MWs) 
and narrow molecular-weight distributions (Scheme 2.2). At the VB-Glu-NCA/PEG-amine 
ratio of 100, the obtained Mn of 20.7 × 10
3 gmol-1 agreed well with the theoretical Mn of 
24.6 × 103 gmol-1 and had a narrow molecular weight distribution of 1.21 (entry 1, Table 
2.1). Two PEG-b-PVBLG copolymers were prepared with degrees of polymerization (DP) 
of 76 (PEG-b-PVBLG76) and 287 (PEG-b-PVBLG287) of the PVBLG block (Table 2.1). 
The ozonation of PEG-b-PVBLG yielded PEG-b-poly(-(4-aldehydebenzyl-L-glutamate) 
(PEG-b-PABLG), which served as the reactive intermediate that, through subsequent 
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hydroamination and reduction with N-(2-aminoethyl)piperidine, yielded the desired PEG-
b-PVBLG76-8 (PEV-L) and PEG-b-PVBLG287-8 (PEV-H). Grafting efficiencies of greater 
than 95% were achieved for both PEV-L and PEV-H (Table 2.2).  
 
 Both PEV-L and PEV-H are highly soluble in water at pH 1-10 (> 50 mg/mL), 
which is drastically different from the corresponding parental (PEG-b-PVBLG) and 
intermediate polymers (PEG-b-PABLG) that are insoluble in water. The excellent water 
solubility of PEV-L and PEV-H is clearly related to their charged side groups, which make 
it possible for the applications of PEV at physiological pH.  Both PEV-L and PEV-H 
showed the characteristic CD spectra of an -helix with two minima at 208 and 222 nm 
(Fig. 2.1a), consistent with our previously reported α-helical conformation of PVBLG-8 
[2,11].  Helical contents of greater than 90% were observed for both PEV-L and PEV-H at 
pH 3 when the side chain amine groups are protonated (Table 2.2). As expected, the charge 
repulsion of the side groups had minimal effect on helix stability because the charged 
amine groups were placed far away from the polypeptide backbone. Furthermore, the 
helicity—as measured by the value of -[]222—was shown to be stable against pH and salt 
changes in the surrounding environment. For example, the -[]222 values of PEV-L and 
PEV-H remained unchanged when the solution pH was increased from 1 to 9 (Fig. 2.1b).  
The helices of PEV-L and PEV-H were also fairly stable in concentrated denaturing 
conditions, such as in 1M NaCl (Fig. 2.1c) and 2M urea (Fig. 2.1d) aqueous solutions. 
These observations suggested that PEVs would maintain their helical conformation in 
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various extracellular and intracellular environments with well-preserved properties 
throughout the gene transfection processes.  
 
2.3.2 Complex formation with PEG-b-PVBLG-8 with DNA 
 The ability of PEG-b-PVBLG-8 to bind and complex with DNA was examined 
using a gel retardation assay. Polymer was mixed with plasmid DNA at DNA:polymer 
weight ratios between 1:1 and 1:60 and run on an agarose gel. The results for PEV-L can 
be seen in Fig. 2.2. The addition of polymer in excess of a 1:2 (DNA:polymer weight ratio) 
resulted in the formation of stable complexes which prohibited the migration of DNA under 
an electrophoretic  force. Interestingly, at a 1:2 DNA:polymer weight ratio, the DNA could 
still be seen in the loading well, indicating incomplete condensation. However, the DNA 
was no longer visible when sufficient polymer was added to achieve a 1:10 DNA:polymer 
weight ratio, indicating complete condensation. As can be seen in Fig. 2.1a, DNA binding 
does not affect the α-helicity of the peptide. 
 
2.3.3 Dynamic light scattering 
 Dynamic light scattering revealed complexes formed between DNA and 
Lipofectamine 2000 at a 1:2 DNA:Lipofectamine 2000 weight ratio to be approximately 
574 nm in diameter. Meanwhile, the hydrodynamic diameter of complexes of PEV-L and 
PEV-H at a 1:40 DNA:polymer weight ratio were substantially smaller—about 107 nm 
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and 246 nm for PEV-L and PEV-H, respectively (Fig. 2.3). Testing of DNA:polymer 
weight ratios less than and greater than 1:40 did not dramatically change the measured 
diameter—provided a minimum amount of polymer was added to achieve complexation. 
For example, the diameter of complexes made with DNA:PEV-L weight ratios of 1:10, 
1:20, 1:40 and 1:80 were 117 nm, 115 nm, 107 nm, and 84 nm, respectively. This suggests 
that once a minimum amount of polypeptide is present—presumably enough to achieve a 
1:10 DNA:polymer weigh ratio based on Fig. 2.2—the excess polymer is not incorporated 
into the complex and exists freely in the solution. Furthermore, despite the rod-like 
structure of the helical polypeptide, complexes formed between DNA and PEG-PVBLG-8 
possessed a globular structure under TEM (Fig. 2.4). Zeta potential measurements were 
performed to ensure that the complex formed between PEV-L (or PEV-H) and DNA were 
overall positively charged. PEV/DNA complexes formed possessed zeta potentials 
between 2 and 10 mV (Fig. 2.5), while PVBLG-8/DNA complexes possessed zeta 
potentials between 20 and 30 mV (data not shown). The addition of PEG block to the 
polypeptide shielded the cationic charge of the PVBLG-8 block.  
 
2.3.4 Toxicity 
 The toxicity of the PEV-H was compared with PVBLG-8 homopolymer (P0) and 
Lipofectamine 2000 via MTT assays in IMR-90 cells. PVBLG-8 (P0) was found to be 
notably toxic to IMR-90 cells.  At 1:40 DNA:polymer weight ratio, a viability of 6% was 
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observed.  The new diblock polymers of both low (PEV-L) and high (PEV-H) molecular 
weight showed substantially reduced toxicity to IMR-90 cells (Fig. 2.6). Increasing 
DNA:polymer ratio resulted in increased toxicity for both PEV-L and PEV-H polymers. 
PEV-H/DNA complexes showed slightly reduced toxicity compared to PEV-L/DNA 
complex, but both PEV-L- and PEV-H polymers were less toxic than Lipofectamine 2000 
under similar condition.   
 
2.3.5 Transfection 
 Transfection experiments were performed with the diblock co-polymers to 
determine if their reduced toxicity impacted their ability to effectively delivery genes to 
IMR-90 cells. As shown in Fig. 2.7, the commercial reagent Lipofectamine 2000 resulted 
in approximately 19% of treated cells expressing the delivered GFP transgene. Unmodified 
PVBLG-8 (P0), on the other hand, had a transfection efficiency of only 1.4% with low cell 
viability. While PVBLG-8 performed comparable to Lipofectamine 2000 in COS-7 and 
HeLa cells in previous studies, its poor performance as shown in Fig. 7 is likely due to the 
excessive toxicity of the polypeptide in IMR-90 cells. Reducing the toxicity of PVBLG-8 
through the addition of PEG blocks resulted in an increased IMR-90 transfection efficiency 
to 9.4% and 21.4% for PEV-L and PEV-H, respectively. Because of the reduced toxicity 
of PEV-L and PEV-H, the DNA dosage could be increased from 1 µg to 2 µg, which 
resulted in slightly higher transfection efficiencies, 13% and 27%, for PEV-L and PEV-H 
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formulations, respectively (data not shown). Although this increase in efficiency was 
modest, it should be highlighted that the diblock polymers appeared to have reduced 
toxicity. For example, even though both Lipofectamine 2000- and PEV-H-transfected cells 
expressed similar amount of GFP in Figure 2.8, the cells transfected with PEV-H possessed 
an overall healthier phenotype with flat and elongated shapes as opposed to cells 
transfected with Lipofectamine 2000 that appeared to be sparse and rounded. 
 
 To further demonstrate the application of PEG-b-PVBLG-8, I next evaluated the 
gene delivery efficiency to the H1 hESCs. PEV-H transfection in separated H1 cells 
resulted in higher transfection efficiency than in cells plated as colonies (Fig. 2.9, 2.10). 
Moreover, the polymer was shown to have no impact on hESC pluripotency 48 h post-
transfection. This was evidenced by the similar expression of stage specific embryonic 
antigen-4 (SSEA-4) both before and after transfection in colonies and single cells (Fig. 
2.11). Further evidence of pluripotency was shown through a western blot of the OCT4 
pluripotency transcription factor before and after transfection with PEV-H (Fig. 2.12). 
Combined with its efficiency, the mild cell impact of the PEV-H made it a promising 
reagent to manipulate the gene expression of human stem cells. 
 
2.4 Discussion 
 Transfection efficiency is often limited due to the toxicity of vectors. Generally, the 
more efficient the transfection material, the greater impact it may have on cell health. This 
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is largely due to the requirements of effective gene delivery—namely, a high polycationic 
charge to condense DNA and enable cell surface binding and membrane-lytic properties to 
facilitate intracellular escape from endocytic vesicles. While good for the delivery of 
nucleic acids, highly cationic materials can also bind and interfere with the function of 
necessary proteins within the cell. Moreover, the membrane lytic effect of materials can be 
unspecific and may act in desirable as well as undesirable manners. Effective gene delivery 
materials are able to balance their positive and negative tendencies so that they are efficient 
enough to allow macromolecules like DNA to enter the cells but safe enough that the cells 
are not irreparably damaged during the process. In my dissertation, I focus on the 
previously described PVBLG-8 materials and try to reduce their overall toxicity while 
maintaining their effective gene delivery performance. 
 
 Previous characterization of the helical polypeptide PVBLG-8 revealed that it can 
operate as an effective delivery vector for both DNA and siRNA [2]. In both cases, its 
performance was demonstrated to be tied to its ability to form stable helices that cause pore 
formation within membranes. In the case of DNA delivery, the membrane lytic potential 
was essential to the escape of DNA-polypeptide complexes from endocytic vesicles. In the 
case of siRNA delivery, the helical PVBLG-8 caused pore formation within cells 
membranes to allow the non-endocytic diffusion of siRNA into the cell cytosol. Therefore, 
in our desire to reduce the toxicity of the PVBLG-8 materials, it was also essential to retain 
their helical structure. Unfortunately, just as helicity makes the materials effective delivery 
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agents, it is also a contributing factor to overall toxicity. As such, I sought a strategy to 
append charge-shielding materials to the helical PVBLG-8. By shielding the positive 
charge, the toxicity of the material should be minimized by reducing its electrostatic 
attraction with negatively charged cell membranes. At the same time, since the helicity of 
the PVBLG-8 block was maintained (Fig. 2.1a), I believed that the material would retain 
its ability to effectively escape the endosome and mediate effective gene delivery (Scheme 
2.1).  
 
 To test the feasibility of incorporation of charge shielding groups, PEG was 
covalently conjugated with PVBLG-8 to yield the diblock polymer PEG-b-PVBLG-8. The 
PEG used had a MW of 5000 Da (DP of 113) and was conjugated to helical PVBLG-8 with 
DPs of 76 and 287 to yield the diblock materials PEV-L and PEV-H, respectively (Scheme 
2.2). Circular dichroism experiments revealed that the incorporation of PEG did not alter 
the presence and stability of the helices even after the DNA is bound and condensed by the 
peptide (Fig. 2.1a). Moreover, the materials were also able to bind and condense plasmid 
DNA into spherical particles with diameters on the order of 100 nm (Fig. 2.2–2.4). Despite 
the inclusion of PEG, these particles were demonstrated to retain an overall positive surface 
charge similar to commercial materials like Lipofectamine 2000 by analyzing their surface 
zeta potential (Fig. 2.5). 
 
 Toxicity measurements with the diblock materials revealed that the inclusion of a 
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PEG block substantially increased the biocompatibility of the materials in IMR-90 cells. 
For example, treatment with the unmodified PVBLG-8 left only approximately 5% of 
IMR-90 cells viability. However, with the addition of a PEG block, cell viability increased 
dramatically and was less toxic than Lipofectamine 2000 (Fig. 2.6). With its improved 
toxicity profile, PEG-b-PVBLG-8 was able to mediate effective transfection in IMR-90 
cells. Previously, the toxicity of the materials was so extreme that only 1.4% of cells were 
successfully transfected. With the reduced toxicity, that number was increased to 
approximately 20%—an increase of approximately 14-fold. With its improved safety 
profile, PEG-b-PVBLG-8 was mild enough to transfect H1 human embryonic stem cells 
without affecting the expression of cell pluripotency markers (Fig. 2.9-2.12).  
 
2.5 Conclusion 
I prepared diblock copolymers consisting of poly(ethylene glycol)-block-poly(γ-4-
(((2-(piperidin-1-yl)ethyl)amino)methyl)-benzyl-L-glutamate) (PEG-b-PVBLG-8) and 
evaluated their capability to mediate gene delivery in IMR-90 human fetal lung fibroblasts 
and human embryonic stem cells (hESCs). The PEG-b-PVBLG-8 contained a membrane-
disruptive, cationic, helical polypeptide block (PVBLG-8) for complexing with DNA and 
a hydrophilic PEG block to improve the biocompatibility of the gene delivery vehicle.  
PEG-b-PVBLG-8 copolymers with low (n = 76) and high (n = 287) degrees of 
polymerization (n) of the PVBLG-8 block were synthesized. I found that the incorporation 
of PEG effectively reduced the toxicity of the helical PVBLG-8 block without dramatically 
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compromising the complexation of copolymers with DNA and their transfection 
efficiencies. PEG-b-PVBLG-8 diblock polymer with a high degree of polymerization had 
a greater transfection efficiency and lower toxicity in IMR-90 cells than the commercial 
reagent Lipofectamine 2000. The usefulness of PEG-b-PVBLG-8 was further 
demonstrated via the successful transfection of hESCs without a measured loss in cell 
pluripotency markers. In contrast to many other polymer- and lipid-based transfection 
systems which utilize the proton sponge mechanism (e.g. polyethylenimine) or lipid mixing 
(e.g. DOTAP, DOPE, etc.) to facilitate endosomal escape, the peptides described here make 
use of a novel pore formation mechanism.  As endocytic escape is generally considered 
one of the most challenging aspects of gene delivery, this alternative endosomolytic 
mechanism may prove useful when working with cell lines not readily amenable to 
transfection by current methods (i.e. IMR-90 and hES cells). This method of the PEG 
modification onto the PVBLG-8 backbone proved to be quite tedious and hard to control, 
to scale up the diblock polypeptide is quite costly and difficult. Therefore, an alternative 
gene delivery system that uses the cationic helical peptide was developed to take advantage 
of the endosomal escape of the nanocomplexes.  
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2.6 Figures 
Scheme 2.1: Plasmid DNA condensation by PEG-b-PVBLG-8 and the uptake 
and release of DNA inside the cell. 
+
+
+
+
+
+ DNA of Interest
-- -- -
-- -- -
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Scheme 2.2: The chemical route for preparation of PEG-b-PVBLG-8 from VB-Glu-
NCA. (i) mPEG113-NH2, TBD, nitrobenzene; (ii) benzyl chloroformate, diisopropyl 
ethyl amine, tetrabutylammonium floride; (iii) O3, CHCl3, -78°C, Me2S; (iv) x, 
Borane-pyridine; (v) HCl 
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Table 2.1. PEG113-NH2 Initiated Polymerization of VB-Glu-NCA. 
Product 
M:Amine:
TBDa 
Time (h) Conv. (%) 
Mn (Mn*) (× 
103 g/mol)b 
MWD 
PEG113-b-PVBLG76 100:1:0.1 24 80 20.7 (24.6) 1.21 
PEG113-b-PVBLG287 400:1:0.1 60 78 75.3 (81.4) 1.29 
aTBD: 1,5,7-triazabicyclo[4.4.0]dec-5-ene; b the MW obtained (theoretical MW = Mn, 
PEG + 245.27 × conv. × [M]/[I]).  
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Table 2.2. Synthesis and conformation analysis of PEG-b-PVBLG-8.a 
Starting Polymer Product 
Grafting 
Eff. (%)b 
[θ]222 (103deg 
cm2/dmol)c 
Helical 
Content 
(%)d 
PEG113-b-PABLG76 
PEG113-b-PVBLG76-8 
(PEV-L) 
> 95 32.8 91.8 
PEG113-b-PABLG287 
PEG113-b-PVBLG287-
8 (PEV-H) 
> 95 34.6 96.4 
a Reducing reagent (5 molar equiv) was used.  Reaction was carried out for 48 h at 50oC.    
bThe grafting efficiency was determined by 1H NMR analysis; cThe mean residue molar 
ellipticity was calculated by following literature-reported formulas: Ellipticity ([θ]222 nm in cm2 
deg dmol−1) = (millidegrees × mean residue weight)/(path length in millimeters × 
concentration of polypeptide in mg mL−1); dThe α-helix contents of the polypeptides were 
calculated using the following equation: % α-helix = (-[]222 + 3000)/39,000 [10]. 
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Figure 2.1: Demonstration of helicity of PEV (a) CD spectra in water of PEV-
L,PEV-H, DNA/PEV-L, and DNA/PEV-H at 1:40 weight ratio at pH 3. (b) The pH 
dependence of the residue molar ellipticity at 222 nm for PEV-L and PEV-H at 
0.05 mg/mL. (c) Salt dependence of residue ellipticity at 222 nm for PEV (d) The 
helical stabilities of PEV-L and PEV-H at pH 3 and 0.05 mg mL−1 in the 
presence of urea. 
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Figure 2.2: DNA/Polymer complex analysis: Gel Retardation of the PEV-L at 
different DNA to polymer weight ratios. 
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Figure 2.3: Particle size analysis of the PEV-L copolymer and DNA complex with 
different PVBLG-8 chain lengths and DNA to polymer weight ratios. 
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Figure 2.4: TEM image of PEV-L with DNA nanocomplex. Scale bar: 200 nm 
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Figure 2.5: Particle zeta-potential of the PEV-L copolymer and DNA complex with 
different PVBLG-8 chain lengths and DNA to polymer weight ratios. 
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Figure 2.6: In-vitro analysis in IMR90 cells. MTT cell viability assay of the 
DNA/polymer nanocomplex with different polymers and at different weight ratios in 
IMR90. 
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Figure 2.7: Initial testing for PEV-L along with Lipofectamine 2000 (Lip) and 
PVBLG-8 (P0) with varying pEGFP-N1 plasmid and polymer amount. Transfection 
efficiency was analyzed 48 hours post transfection with flow cytometry. 
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Figure 2.8: Fluorescent images of the transfection using Lipofectamine and 
PEV-H. Scale bar: 250 µm 
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Figure 2.9: EGFP plasmid transfection efficiency using Lipofectamine 2000 and 
PEV-H of hESC H1 as small colonies 
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Figure 2.10: EGFP plasmid transfection efficiency using Lipofectamine 2000 and 
PEV-H of hESC H1 as single cells as analysed by flow cytometry. 
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Figure 2.12: Western blot of cells isolated 72 h post transfection demonstrating 
the protein expression of OCT4 in hESC H1 cells. 
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Chapter 3: 
 
Coating of cationic, helical peptide with hyaluronic acid for 
smart, safe, and targeted non-viral gene delivery 
 
 
Significant portions of this chapter were published as "Enhanced Non-Viral Gene Delivery 
to Human Embryonic Stem Cells via Small Molecule-Mediated Transient Alteration of 
Cell Structure" Jonathan Yen, Lichen Yin, and Jianjun Cheng, J. Mat. Chem. B., 2014, 2, 
8098-8105. 
 
3.1 Introduction 
PVBLG-8 has been demonstrated as a gene delivery system with high membrane 
activity and endosomal escape, which can be attributed to the cationic helicity and rigid 
structure[1]. Although PVBLG-8 showed some gene transfection in hESCs, it also 
exhibited remarkable cytotoxicity to the cells due to the cationic helical characteristics of 
the peptide[1]. There is a fine balance between the transfection efficiency and toxicity of 
cationic helical peptides. There have been chemical methods to modify the cationic helical 
peptide to reduce its toxicity, like structural reconfiguration[2], conjugations[3-6], and 
triggered degradation of the material [7].These modifications can effectively reduce the 
toxicity through the reduction of the cationic charge density on the peptide, while retaining 
its transfection efficiency. Yet, the conjugation of PEG onto PVBLG-8 as I described 
earlier was tedious and not easily tuneable.  
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Herein, I decided to take a formulative approach to develop a new gene delivery 
system based on self-assembled DNA/PVBLG-8 nanocomplexes coated by negatively 
charged hyaluronic acid (HA). HA can target and specifically bind to CD44, a known 
receptor specific to HA with high expression level in hESCs[8]. HA has been used in 
nanomedicine to target tumors, which also have high CD44 expression levels[9-14]. By 
coating the nanocomplexes with HA, it not only shields the charges to decrease the toxicity, 
but also acts as a targeting moiety for receptor-based endocytosis through HA/CD44 
interactions. Furthermore, the HA can be deshielded through the pH drop and actions of 
endogenous hyaluronidase after internalization to expose the cationic helical peptides, 
allowing rapid and efficient endosomal release and expression of DNA plasmids. The HA 
coated nanocomplex demonstrates three important characteristics that enhance gene 
transfection efficacy in hESCs; an outer shell with active targeting moiety against CD44, 
an enzyme and pH sensitive targeting shell that can be released in the endosome exposing 
the cationic helical peptides, and the cationic helical peptides which can effectively allow 
for endosomal escape (Scheme 3.1). 
 
3.2. Materials and Methods 
3.2.1 General 
 hESCs H1 (hESC-H1) was cultured in E8 medium from Stem Cell Technologies 
(Vancouver, Canada). Y-27632 was purchased from Stemgent (Cambridge, MA, USA). 
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YOYO-1 was purchased from Invitrogen (Carlsbad, CA, USA). pEGFP-N1 was obtained 
from Elim Biopharmaceuticals (Hayward, CA, USA). Milli-Mark™ Anti-SSEA-4-PE was 
purchased from EMD Millipore (Billerica, MA, USA). PVBLG-8, a helical cationic 
polypeptide with a polymerization degree of 200, was synthesized following our reported 
procedures [15]. 
 
3.2.2 Instrumentation 
Flow cytometry analysis was conducted on a BD LSRII flow cytometry analyzer 
(Becton Dickinson, Franklin Lakes, NJ). Cells were visualized with a Zeiss Axiovert 40 
CFL fluorescence microscope equipped with a 10 and 20x objective (Thornwood, NY). 
Zeta potential and size analysis was conducted on the Malvern Zetasizer (Worcestershire, 
UK). 
 
3.2.3 Nanocomplex formation and characterization  
Various non-viral vectors were used for the transfection analyses. Plasmid DNA (1 
µL, 1mg/mL) was diluted in water (25 µL). PVBLG-8 (7.5μL, 1 mg/mL) was diluted with 
water (25 µL). For the PVBLG-8 and coated nanocomplex procedures, the PVBLG-8 and 
plasmids were mixed at various w:w ratios and were incubated for 20 m at rt for complex 
formation. Hyaluronic acid (2.5-50μL,1mg/mL), dissolved in water, was added to the 
nanocomplex mixture and incubated for another 20 m at rt. For the mixed system, the DNA 
and hyaluronic acid were first mixed together at various w:w ratios and then the PVBLG-
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8 was added at various ratios. The mixture was incubated at rt for 30 m for complex 
formation. Dynamic light scattering (DLS) and zeta potential analysis was conducted on 
the samples with a Malvern Zetasizer (Worcestershire, UK). 
 
The nanocomplexes were subjected to electrophoresis in 1% agarose gel at 100 V 
for 45 minutes to evaluate DNA condensation by the polypeptides in terms of DNA 
migration.  
 
3.2.4 In-vitro Gene Transfection 
Cells were seeded in matrigel coated 24 well plates as single cells using accutase 
and incubated for 24 hours with rho-kinase inhibitor Y-27632 (10 μM). Using fresh low 
protein and serum free E8 medium, nanocomplexes as described earlier were added at 1μg 
DNA/well. After incubation for 4 h, the medium was replaced with fresh E8 medium and 
cells were cultured for 48 h. The cells were collected with accutase, fixed with 
paraformaldehyde and analyzed using flow cytometry to determine transfection efficiency. 
 
3.2.5 In-vitro HA blocking 
hESCs were incubated with free hyaluronic acid (300kDa, 1-5mg/mL) for 1 h prior 
to transfection. The cells were then washed 1x with PBS and placed back with fresh E8 
media. The nanoparticles were added to the cells at 1 µg DNA/well. After incubation for 4 
h, the medium was replaced with fresh E8 medium and cells were cultured for 48 h. The 
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cells were collected with accutase, fixed with paraformaldehyde and analyzed using flow 
cytometry to determine transfection efficiency. 
 
3.2.6 pH and hyaluronidase exposure of nanocomplex 
Nanocomplexes were formulated as previous described. HA coated nanocomplexes 
(400 µL, 100 µg/mL DNA) were incubated with hyaluronidase (100 µL, 0.5 mg/mL) in 
phosphate and citric acid buffer with a pH of 7.4, 6.8, 6.2 or 5.6 for 0, 30, or 120 m at 37°C. 
The HA coated nanocomplexes (100 µL) were then diluted in their corresponding buffer 
and the zeta potential of the resulting particles were analysed with the Zetasizer. 
 
To test the membrane activity of the nanoparticles, Large Unilamellar Vesicles by 
Extrusion Technique (LUVETS)[16] loaded with 8-aminonaphthalene-1,3,6-trisulfonic 
acid (ANTS) and p-xylene-bis-pyridinium bromide (DPX) were formulated[17]. 
Briefly,DOPC (100 µL, 25 mg/mL CHCl3) and POPC (1 mL, 10 mg/mL CHCl3) were 
mixed in round bottom flask and evaporated with a rotary evaporator to create dry thin 
film. The film was allowed to dry overnight under vacuum. The lipid film was rehydrated 
by 5 mL of ANTS/DPX solution (12.5 mM ANTS, 45 mM DPX, 10 mM phosphate buffer, 
pH 7.4) for 30 m at rt. The solution was then put through 5 freeze thaw cycles in liquid 
nitrogen and like warm water. The solution was then extruded 15 times through 0.4 µM 
polycarbonate membranes. Any extravesicular components were removed through a 
Sephadex G-50 gel filtration column.  
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Nanocomplexes were formulated as previous described. HA coated nanocomplexes 
(400 µL, 100 µg/mL DNA) were incubated with hyaluronidase (100 µL, 0.5 mg/mL) in 
phosphate and citric acid buffer with a pH of 7.4 or 6.8 for 0 or 30 m at 37°C. The HA 
coated nanocomplexes (10 µL) and the ANTS/DPX LUVETs (5 µL) were mixed diluted 
in a final solution of the corresponding buffer of 100 µL. Triton x was used as the positive 
control. The leaked ANTS dye was measured using a plate reader at 360 nm excitation and 
530 nm emission. The final leakage percentage was calculated using the ratio of 
fluorescence of the sample with the positive control after background subtraction.  
 
3.2.7 Cell viability 
Cells were seeded in matrigel coated 96 well plates as single cells using accutase 
and incubated for 24 hours with y-27632 (10 µM). Using fresh low protein and serum free 
E8 medium, nanocomplexes were added at 0.2µg DNA/well. After incubation for 4 h, the 
medium was replaced with fresh E8 medium and cells were cultured for 48 hours. Cell 
viability was evaluated through a MTT assay. Cells without complex treatment served as 
the control and results were expressed as percentage viability of control cells.  
 
3.2.8 Intracellular Uptake Studies 
DNA (1 mg/mL) was mixed and labeled with YOYO-1 (20 µM) at one dye 
molecule per 50bp of DNA. The HA coated nanocomplexes were then formed with 
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YOYO-1/DNA as discussed before at a DNA:PVBLG-8:HA weight ratio of 1:7.5:7.5. 
hESCs were plated on matrigel coated 24-well plate and allowed to grow to medium sized 
colonies. The complexes were added to the wells at 1 µg of YOYO-1-DNA per well and 
incubated for 4 h at 37°C. The cells were then quantified through flow cytometry to 
quantify YOYO-1 uptake. Results are expressed as mean fluorescence levels. 
 
To elucidate the mechanisms regarding the cellular internalization of 
DNA/PVBLG-8/HA complexes, the uptake study was performed at 4 °C or in the presence 
of various endocytic inhibitors for 2 h. Cells were pre-treated with chlorpromazine (10 
µg/mL), genistein (200 µg/mL), dynasore (80 µM), and wortmannin (50 nm) for 30 min 
before the complexes were added and throughout the experiment for 2 h at 37°C. Results 
are expressed as percentage mean GFP fluorescence level at 37 °C in control cells in the 
absence of endocytic inhibitors. 
 
3.2.9 Western blot analysis and SSEA staining 
After 72 h, the cells were stained with DAPI (250 µL, 3 nM) and SSEA-4–PE (250 
µL, 0.02 mg/mL), a pluripotency cell marker, for 30 min at 37 °C. After 5 d, the cells were 
collected with RIPA buffer and mixed with Laemmli buffer supplemented with 2-
Mercaptoethanol and heated for 5 m at 100°C to denature the proteins and then put on ice. 
The samples were ran on 10% SDS PAGE Gel at 120 V for 1.5 h, and wet transferred to 
the nitrocellulose membrane using the AMRESCO Rapid Western Blot Kit per 
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manufacturer’s instructions. The membrane was stained with OCT4 and α-Tubulin primary 
antibodies and then with HRP-tagged secondaries.  
 
3.3. Results 
3.3.1 Characterization of DNA:PVBLG-8:HA Nanocomplexes 
DNA condensation by PVBLG-8 followed by HA coating was evaluated by gel 
retardation assay. As shown in Fig. 3.1, DNA can be bind tightly to PVBLG-8 with a 
weight feed ratio at 1:7.5,and the coating of HA on the nanocomplex did not disrupt or 
displace the DNA in the nanocomplexes even when the feeding ratio of DNA to PVBLG-
8 to HA at 1:7.5:50. This result indicated that the complexes are relatively stable through 
the coating method, and the negative charges on the HA does not interfere in the assembly 
or disassemble the nanocomplexes. Yet, when the HA was mixed directly with the DNA 
and PVBLG-8, the complex was unstable and some DNA leakage was detected (Fig. 3.2). 
 
The size and zeta potential of the DNA/PVBLG-8 nanocomplexes at 1:7.5 weight 
ratios with varying HA weight ratio coatings were characterized using the DLS and 
zetasizer. Without HA coating, the nanocomplex size was 57.9 nm in diameter. After the 
coating of HA, at between 1:7.5:5 and 1:7.5:15 weight ratios, the effective diameters 
increased to around 170 nm. With further addition of HA to 1:7.5:50, the diameter 
increased to 270 nm. The zeta potential of the nanocomplex without HA, measured to be 
19.2 mV, decreased to 11.1 mV with HA coating at 1:7.5:1 ratio indicating that the 
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nanocomplexes retained their positive charges. The zeta potential then decreases to 
between -18 and -25 mV when the ratio of HA was between 1:7.5:5 and 1:7.5:15 and then 
drops to -42 mv at 1:7.5:50. The increase and stabilization of the size and zeta potential 
demonstrates that the nanocomplexes were successfully coated with HA (Fig. 3.3).  
 
The stability of the nanocomplexes was tested through the use of the dynamic light 
scattering to determine the size of the nanoparticles over time. The particles were tested at 
30 min and 4 h after formulation at 37°C. As previously demonstrated, the size of the 
nanocomplexes with HA coating ranged from 150-180 nm and less than a hundred nm 
without the HA coating. Thus, if the HA coating were to come off or be destabilized, the 
size of the nanocomplex would become smaller. The sizes of nanocomplex remained 
constant in the different mediums, thus indicating that the nanocomplexes are quite stable 
(Fig. 3.4). 
 
3.3.2 hESC Transfection with HA Coated DNA/PVBLG-8 Nanocomplexes 
Through the optimization of various DNA:PVBLG-8 weight ratios, 1:7.5 is the 
optimal ratio for the highest transfection efficiency (Fig. 3.5). Thus, the 1:7.5 ratio was 
used with various ratios of HA coating on the nanocomplexes. Without HA coating, the 
nanocomplexes achieved 22% transfection efficiency, while with the increased ratio of HA 
coated on the nanocomplexes, the transfection efficiency went up to 28%, 27% and 30% 
for 7.5:2.5, 7.5:5, 7.5:7.5 of PVBLG-8:HA ratios, respectively. As the amount of HA was 
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increased to 15 and 30, the transfection efficiency dropped significantly to 20% and 17%, 
respectively (Fig. 3.6).This drop in transfection efficiency can be attributed to the excess 
HA in the system that did not coat the nanocomplexes, which compete for the CD44 
receptors. PVBLG-8 by itself has also proven to be quite toxic to the cells, (Fig. 3.7, 3.17), 
where the cells are unhealthy and littered with cell debris. On the other hand, with HA 
coating the cells demonstrated lower toxicity and higher transfection. The HA coating not 
only acts as a targeting moiety, but also significantly counters the charges from the 
PVBLG-8 thus decreasing the overall toxicity in hESCs.  
 
To demonstrate that the targeting of the HA coated nanocomplexes was due to the 
CD44 binding of the HA coated on the surface, pre-treatment of free HA was applied to 
the cells for 30 min and then washed off before transfection. With the treatment of 2.5 and 
5 mg/mL of free HA pre-treated on the cells , a drop of transfections to 8% and 6% were 
shown, respectively, from 35% without pre-treatment (Fig. 3.8). This indicates that free 
HA has bound to the cell surface CD44 receptors and blocked them from further uptake, 
indicating that the CD44/HA interactions are an important aspect to the increased 
transfection efficacy of the nanocomplex. To further demonstrate the importance of the 
CD44 receptor for the system, the HA coated nanocomplexes were transfected in other 
CD44 positive and negative cells, human mesenchymal stem cells (hMSCs) and COS-7 
cells, respectively. For CD44 positive hMSCs, HA coated nanocomplexes showed almost 
twice the transfection efficiency than those without HA coating. On the other hand, in 
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CD44 negative COS-7 cells, without the HA coating, the transfection efficiency was 36% 
and it dropped down to 15% after HA coating (Fig. 3.9). These trends demonstrate the 
important roles the CD44 receptors play in the transfection, which may due to the increased 
uptake of the HA coated nanocomplexes.  
 
3.3.3 Mechanistic Studies of DNA/PVBLG-8/HA Nanocomplexes 
To demonstrate that the enhanced gene transfection is due to the increased uptake 
through the CD44 receptor mediated pathway, the total uptake of DNA was evaluated. 
Using DNA tagged with YOYO-1, an uptake study was done to determine the amount of 
DNA/YOYO-1 uptake into the cells. It can be seen that without HA coating, the mean 
YOYO-1 fluorescence level measured to be about 61%, while with the HA coating at 
1:7.5:7.5 ratio, the mean YOYO-1 fluorescence was significantly higher at 67% (Fig 3.10). 
In addition, with the treatment of free HA, the mean YOYO-1fluorescence level declined 
significantly to around 44%, indicating a reduced nanocomplex uptake. Alternatively, the 
uptake of DNA/YOYO-1 in CD44 negative COS-7 cells is reduced significantly after the 
coating of HA, further demonstrating that the CD44 receptor mediated the uptake of HA 
coating nanocomplex (Fig 3.11). 
 
To show that the HA coated nanoparticles were indeed targeting the CD44 
receptors, hESCs were stained with CD44 antibodies and incubated with HA coated 
DNA/YOYO-1/PVBLG-8nanocomplexes for 2 h at 4°C. Through confocal imaging, CD44 
  
66 
 
is stained uniformly across the surface of the hESCs. The DNA/YOYO-1 can be visualized 
on the cell surface co-localized with the CD44 receptors, indicating the importance of the 
roles of the CD44/HA interactions (Fig 3.12).  
 
To elucidate the mechanisms underlying the cellular internalization of the HA 
coated nanocomplexes, an uptake study at 4°C or in the presence of various endocytic 
inhibitors was performed. Energy dependent endocytosis was blocked at 4°C; clathrin 
mediated endocytosis was blocked by chlorpromazine, which triggers dissociation of the 
clathrin lattice; caveolae was inhibited by genistein and mβCD by inhibiting tyrosine 
kinase and depleting cholesterol, respectively; macropinocytosis was inhibited by 
wortmannin by inhibiting phosphatidyl inositol-3-phosphate[18,19]. When the cells were 
incubated at 4°C, the uptake dropped to almost 3% of the control, while chlorpromazine 
dropped to 62%, genistein dropped to 22%, and wortmannin to 91% of the control (Fig. 
3.13). The dramatic drop of transfection efficiency at 4°C indicates the process is energy 
dependent, and with the drop in uptake with the treatment of chlorpromazine and genistein, 
further demonstrates that the nanocomplexes enters the cells through receptor mediated 
endocytosis.  
 
Due to the quick membrane disruption ability of PVBLG-8, the YOYO-1-DNA can 
quickly escape the endosomes and permeate into the cell cytoplasm after 2 h incubation at 
37°C (Fig. 3.14). Therefore a substitute, poly-lysine, a cationic peptide with lower 
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membrane disruption ability was used to visualize the uptake and localization of the HA 
coated complexes. Through confocal imaging, there is significant co-localization of the 
HA coated YOYO-1-DNA/PLL complex with the lysotracker red stain as seen through 
CLSM confocal imaging (fig 4b). It demonstrates that HA coating helps the nanocomplex 
uptake through receptor mediated endosomal pathway. But it also showed that PVBLG-8 
nanocomplex induces faster and more efficient endosomal escape, which is beneficial for 
gene transfection[1]. PVBLG-8 is exposed to allow for membrane disruption and 
endosomal escape once the nanocomplex reaches the endosomes. 
 
3.3.4 Exposure of PVBLG-8 of HA Coated Nanocomplex for Endosomal Escape 
To demonstrate the endosome triggerable membrane disruption of HA coated 
nanocomplexes for rapid endosomal escape, the nanocomplex zeta potentials and 
membrane disruption abilities were evaluated after treatment with hyaluronidase (HAase) 
at varying endosomal pH. At the initial time point of incubation of the HAase with varying 
pH of 7.4, 6.8, 6.2 and 5.6, the zeta potential remains negative at -21, -17.6, -16.8, and -
10.3 mV, respectively. After 30 min incubation, the zeta potential at pH of 7.4 and 6.8 
increased but remained negative at -18.2 and -8.32 mV, respectively. On the other hand, 
the zeta potential at pH of 6.2, and 5.6, all increased to the positive range of 1.34 and 9.39 
mV, respectively. Finally, after 120 min the zeta potential at pH of 7.4 stays negative at -
9.3 mV. But, for the pH at 6.8, 6.2 and 5.6, the zeta potential increases to positive of 1.69, 
7.2 and 11.8 mV, respectively. A pH of 7.4 is representative of the cytoplasmic pH, while 
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early and late endosomes have a pH of 6.8 and 5.6, respectively[20] (Fig. 3.15). The shift 
of zeta potential towards positive indicates the exposure of the cationic helical peptides, 
which are then capable of membrane disruption.  
 
But to further prove the membrane disruption ability of the HA coated 
nanocomplexes at an early pH endosome of 6.8, large unilamellar vesicles (LUV) were 
synthesized for dye leakage assay. At a pH of 7.4 and 6.8 it can be seen that the non-HA 
coated nanocomplexes allowed for 100% release of the dye. While with HA coating, the 
nanocomplexes only demonstrated slight membrane disruption at pH of 7.4, and a slight 
increase in membrane disruption at a pH of 6.8. Alternatively, with the addition of HAase 
after 30 min incubation at pH of 7.4 and 6.8, the dye leakage increased up to 46% and 76%, 
respectively, indicating strong membrane disruption ability (Fig. 3.16). In addition, 
nanocomplexes using PLL were also studied and it was found that with or without HA 
coating, there was no membrane disruption as expected. These studies indicate that the HA 
coated PVBLG-8 nanocomplex is responsive to the endosomal environment of both the pH 
and HAase activity, allowing for rapid endosomal escape. 
 
3.3.5 Toxicity and Maintenance of hESCs 
Cytotoxicity of the HA coated complexes was evaluated in hESCs 48 h after 
transfection using the MTT assay. PVBLG-8 demonstrated a cell viability of 75% (Fig. 
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3.17). But with the HA coated nanoparticles, the cell viability increased to approximately 
90% with the HA coated at 1:7.5:7.5 weight ratios. 
 
To ensure that the materials did not alter the cell’s behavior or cause any 
differentiation, the cells were stained with SSEA-4 antibodies, stage specific embryonic 
antigen-4, 72 h after transfection, in which the cells all stained positive (Fig. 3.18). In 
addition, cell lysate were collected 5 days after transfection and a western blot was 
conducted to confirm the continued expression of the pluripotent factor, OCT4 (Fig. 3.19). 
The expression of SSEA-4 and OCT4 demonstrates that this system does not cause 
undesired differentiation or interferes with the pluripotency of the hESCs.  
 
3.4. Discussion 
Here, I developed a novel gene transfection system that contains an outer negatively 
charged cell targeting shell consisting of HA, with an inner core made from a cationic 
helical peptide that is able to condense DNA and facilitate endosomal escape. The system 
utilizes the charge interactions between the outer negatively charged shell and positive 
inner shell to be stable at neutral pH, but allows for the deshelling and exposure of the 
positive helical peptides when exposed to a lower pH and HAase with in the endosome. 
With the HA coating of the nanocomplexes, the hESC transfection efficiency of 
DNA/PVBLG-8 nanocomplexes increases significantly, despite the alteration of the 
overall charge of positive to negative. HA is a negatively charged biocompatible 
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polysaccharide that is found naturally in the body and has been used as the backbone of 
many hydrogel systems for stem cell engineering[8]. A few glycosaminoglycans, except 
for hyaluronic acid, have been shown to disrupt cationic polypeptide gene 
transfections[21]. The reversal of charge indicates the loss of the initial membrane 
disruption effect of the cationic helical peptide, which in theory should have decreased 
transfection. However, the negative nanocomplexes increased the transfection efficiency, 
indicating that the HA on the nanocomplexes is an integral part to the transfection 
efficiency, in which they target the CD44 receptors that are expressed on hESC surfaces. 
At up to 1:7.5:7.5 weight ratios, the transfection efficiency increases, then drops with 
additional HA coating. This drop is likely to be caused by the excess HA that were not 
coated on the nanocomplex. This can be seen by the DLS and zetapotential, that after a 
certain ratio, the size and zeta potential of the nanocomplex stays constant. Thus, the excess 
free HA could be competitively binding with the CD44 receptor against the nanoparticles, 
demonstrated by the drastic drop in transfection efficiency with the pre-treatment of HA.  
The drop demonstrates that the free HA has bound to the cell surface CD44 receptors and 
blocked them from further uptake, indicating that the CD44/HA interactions are an 
important aspect to the increased efficacy of the nanocomplex. The HA coated 
nanocomplexes also showed a higher efficacy in CD44 positive hMSCs, yet in CD44 
negative cells, COS-7 cells dropped significantly. The drop in transfection efficiency in 
CD44 negative COS-7 cells with HA coated nanocomplexes, indicates that the CD44 
receptor is indeed an important factor for the uptake of the HA coated nanocomplexes.  
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To understand the mechanism of uptake, I conducted uptake studies of DNA tagged 
with YOYO-1 dye and found that the cells did significantly increase the uptake of the 
nanoparticles with the HA coating. Through the study with various endocytosis inhibitors, 
the uptake was drastically inhibited at 4°C, indicating that the uptake of the particles was 
highly energy dependent. In addition, the decrease of the uptake due to the chlorpromazine, 
demonstrated that some of the particles were taken up through clathrin dependent 
endocytosis. On the other hand, genistein also had a large decrease in uptake of the YOYO-
1/DNA, thus indicating that some of the uptake is due to clathrin independent pathways 
like caveolae mediated uptake. This denotes the importance of the CD44 receptor mediated 
endocytosis. Both CD44[22] receptors and caveolin[23] have been known to be present in 
lipid rafts domains, which are the sites of endocytosis in caveolae mediated endocytosis, 
indicating the localization of the HA nancomplexes at CD44 containing lipid rafts 
domains[24].  
 
Commonly used transfection materials like polyethylenimine and polylysine have 
the ability to condense DNA for non-viral gene delivery, but PEI demonstrates slower 
endosomal release through the proton sponge effect, while polylysine demonstrates no 
endosomal escape[25,26]. Our nanocomplex system transforms to exhibit membrane 
disruptive properties in the endosomal environment of low pH and HAase activity. The 
exposure of PVBLG-8 in the system enhances the endosomal release of the nanocomplex 
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and thus the DNA. When the materials were switched to poly-L-lysine, a non-membrane 
disrupting polymer, there was little endosomal escape, and the nanocomplexes were mainly 
retained in the endosomes. In early endosomes, at a low pH and with some HAase activity, 
the HA coated nanocomplexes demonstrated increased LUV dye leakage due to membrane 
disruption. Our system is superior to other materials, due to our highly available and active 
membrane disruption activity that is initially shielded to reduce cytotoxicity to the cells, 
but is revealed when it enters the endosomes. 
 
Not only did the HA coated nanocomplexes increase transfection efficiency, they 
also lowered the toxic effect of the cationic helical peptide. It also has little effect on the 
cells pluripotency, for the hESCs still proved to be both OCT4 and SSEA4 positive. Thus, 
the use of a targeting moiety for a receptor on hESCs is a step in looking at non-viral gene 
delivery into hESCs differently, in which a cell’s specific mechanism is exploited to 
enhance transfection efficiency.  
 
3.5 Conclusion 
Here I report a new targeting and triggerable gene delivery system for human 
embryonic stem cells based on the PVBLG-8 peptide, a cationic helical peptide with high 
membrane disruption properties. The DNA/PVBLG-8 nanocomplex by itself proves to be 
toxic to the cells due to the high membrane disruption properties. Using HA as a coating 
for the nanocomplexes not only decreases the toxicity from the cationic helical peptides, 
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but allows a specific targeting moiety for hESCs that increases the uptake and release of 
DNA, which in turn increases the transfection efficiency. But after the material is taken up 
through endocytosis, the low pH and HAase are able to degrade and the HA on the 
nanocomplex is removed exposing the positive peptides and allowing for endosomal 
escape through membrane disruption. This provides a promising approach for 
manipulation of hESCs or pluripotent stem cells through transient gene delivery, 
overcoming major hurdles towards development of many biomedical applications. 
Increased gene transfection efficiency reduces the need for enrichment and sorting of the 
manipulated pluripotent stem cells. These preliminary studies lead to further possibilities 
of selective gene delivery to undifferentiated hESCs and potential further modification of 
the HA coating for PVBLG-8 based in-vivo gene delivery to other CD44 positive cells. The 
use of HA to target and enhance the non-viral gene delivery system provides an alternative 
method that does not just rely on the chemical characteristics of the material for gene 
delivery, but also targets and takes advantage of the biological properties of hESCs. Given 
this information, I then looked further into other physiological properties of hESCs I could 
use to further enhance gene transfection efficiency. 
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3.6 Figures 
 
Scheme 3.1: Formulation and uptake route of the hyaluronic acid coated 
PVBLG-8/DNA nanocomplexes 
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Figure 3.1: Gel Retardation of HA coated nanocomplexes at varying 
DNA:PVBLG-8 weight ratios. 
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Figure 3.2: Gel Retardation of HA coated nanocomplexes at varying 
DNA:PVBLG-8 weight ratios. 
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Figure 3.3: Size and zeta potential of HA coated nanocomplexes at 1:7.5 
DNA:PVBLG-8 weight ratios. 
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Figure 3.4: Stability of HA coated nanocomplexes at 1:7.5:7.5 DNA:PVBLG-8:HA 
weight ratios in water, PBS and E8 medium as determine by size change 
measured by DLS. 
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Figure 3.5: Gene transfection optimization at varying DNA:PVBLG-8:HA coating 
ratios (w:w:w). 
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Figure 3.6: Transfection of hESCs with varying ratios of HA coating on 
DNA:PVBLG-8 nanocomplexes. 
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Figure 3.7: Fluorescence images of H1 hESCs 48 h post transfection with and 
without HA coated nanocomplexes and with 5 mg/mL free HA pretreatment. Scale 
bar: 250 µm 
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Figure 3.8: Transfection of 1:7.5:7.5 nanocomplexes in cells pretreated with 0, 2.5 
or 5 mg/mL of free HA. 
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Figure 3.9: Transfection comparison between CD44+ hMSCs and hESCs, and CD44- 
COS-7 cells to demonstrate the effect of HA targeting. 
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Figure 3.10: Cell uptake level of PVBLG-8/YOYO-1-DNA complexes in hESCs 
with varying amounts of HA coating and with the pretreatment of hESCs with free 
HA (n =3). 
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Figure 3.11: Cell uptake level of YOYO-1-DNA /PVBLG-8 complexes with and 
without HA coating in CD44 negative COS-7 cells at 1:7.5 weight ratios (n =3).  
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Figure 3.12: CLSM images of hESCs incubated with HA coated PVBLG-8/YOYO-
1-DNA complexes at 4° C for 1 h with CD44 antibody staining. Scale bar: 10 µm 
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Figure 3.13: Cell uptake mechanisms HA coated PVBLG-8/YOYO-1-DNA 
complexes in hESCs through the pre-treatment and treatment of various 
endocytotis inhibitors (n=3). 
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Figure 3.14: CLSM images of uptake of HA coated PVBLG-8/YOYO-1-DNA and 
Poly-L-lysine/YOYO-1-DNA complexes and with Lysotracker staining. Scale bar: 
10 µm 
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Figure 3.15: pH and HAase effect on HA coated nanocomplexes. Changes in the 
the zeta potential of DNA/PVBLG-8/HA nanocomplexes after treatment with 0.5 
mg/mL of HAase at different pH values for different times. 
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Figure 3.16: pH and HAase effect on HA coated nanocomplexes. ANTS/DPX 
loaded LUVET leakage study of different nanocomplexes with and without the 
HAase treatment at different pH values. 
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Figure 3.17: Cell viability of hESCs at varying ratios of HA coating of 
nanocomplexes as determined by MTT assay 
  
0
20
40
60
80
100
120
1:7.5:0 1:7.5:5 1:7.5:7.5 1:7.5:10 1:7.5:15
C
e
ll 
V
ia
b
ili
ty
 (
%
)
DNA:PVBLG-8:HA weight ratio
**
  
92 
 
 
Figure 3.18: DAPI and SSEA4 staining patterns of hESCs 72 h after transfected 
with HA coated nanocomplexes. Scale bar: 250 µm 
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Figure 3.19: Western blot analysis on the OCT4 expression in hESCs 5 days post 
HA coated nanocomplexes transfection. 
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Chapter 4: 
Enhancement of gene delivery into human embryonic stem 
cells 
4.1 Introduction 
Considering the colony-forming properties of hESCs that limit non-viral gene 
delivery, I hypothesized that increasing cell spreading would increase cellular uptake and 
thus the gene transfection efficiency. Growing hESCs on stiffer substrates has shown to 
disperse cells and promote cell spreading[1,2], and it has also been shown in other cell 
types that an increase in the substrate stiffness can lead to higher transfection efficiency[3]. 
However, such an approach not feasible for hESCs, mainly due to the sensitive nature of 
hESCs to their external environment. It has been reported that hESCs grown on stiff 
substrates will start differentiating[4], but it indicates that cellular uptake is intrinsic to the 
stiffness and structure of the cells, and a decrease in membrane tension and contractility 
would lead to increased cellular spreading[5] and stimulate endocytosis[6]. 
 
Dissociation of hESCs into single cells or small colonies can potentially facilitate 
cell spreading. However, since hESCs are considered to be in the primed state, they are 
intolerant to single cell passaging and usually exhibit <1% clonal efficiency due to 
apoptosis upon cellular detachment and dissociation[7]. Rho-associated kinase (ROCK) 
inhibitor has been used to diminish dissociation-induced apoptosis, resulting in increased 
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survival of individual hESCs[7]. By pre-treatment of the hESCs with Y-27632 (10 µM) for 
an hour before single cell dissociation, the cloning efficiency increased to 27%. Cells 
treated with Y-27632 maintain their pluripotency and morphology for at least 5 passages 
and are able to differentiate into neural cells[7]. Therefore, with an attempt to facilitate 
hESC spreading without causing apoptosis, the selective ROCK inhibitor, Y-27632, was 
used to alter the cell’s myosin fibers and mimic the cell's structure when grown on a stiffer 
substrate by inhibiting non-myosin IIA[8,9]. Y-27632 is also known to decrease cell-
generated tension[10]. I hypothesized that Y-27632 would facilitate the spreading and 
flattening of hESCs colonies on plates due to decreased membrane tension, which would 
then increase the surface area exposure to allow for a more efficient uptake of gene delivery 
vectors and promote the gene transfection (Scheme 4.1). A broad spectrum of non-viral 
gene delivery vectors, including commercially available reagents (Lipofectamine 2000 
(LPF), Fugene HD (FHD), poly-L-lysine (PLL), poly-L-arginine (PLR), and 
polyethyleneimine (PEI)), were evaluated in terms of their transfection efficiencies in the 
presence or absence of Y-27632. Mechanistic analysis into the effect of Y-27632 on cell 
spreading, cell uptake property, and pluripotency of hESCs was also performed. The 
treatment of hESCs with Y-27632 was revealed to significantly increase transfection 
efficiency of all the tested materials by 1.5 to 2 fold in hESCs, establishing an alternative 
use of Y-27632 as a tool for enhanced non-viral gene delivery. 
 
4.2. Materials and Methods 
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4.2.1. General 
 Human embryonic stem cell line H1 (hESC-H1) was cultured in mTeSR 1 medium 
from Stem Cell Technologies (Vancouver, Canada). Fugene HD (FHD) was purchased 
from Promega (Madison, WI, USA). Y-27632 was purchased from Stemgent (Cambridge, 
MA, USA). Opti-MEM, Lipofectamine 2000 (LPF), and YOYO-1 were purchased from 
Invitrogen (Carlsbad, CA, USA). pEGFP-N1 was obtained from Elim Biopharmaceuticals 
(Hayward, CA, USA). Milli-Mark™ Anti-SSEA-4-PE was purchased from EMD 
Millipore (Billerica, MA, USA). PLL, PLR, and PEI were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).  
 
4.2.2. Instrumentation 
Flow cytometry analysis was conducted on a BD LSRII color flow cytometry 
analyzer (Becton Dickinson, Franklin Lakes, NJ). Cells were visualized with a Zeiss 
Axiovert 40 CFL fluorescence microscope equipped with a 10x and 20x objective 
(Thornwood, NY). Fluorescence imaging was done using the GE InCell Analyzer 2000 
from GE Healthcare Sciences (Piscataway, NJ, USA). Zeta potential and size analysis were 
conducted on a Malvern Zetasizer (Worcestershire, UK). 
 
4.2.3 Preparation and characterization of nanocomplexes 
Various non-viral vectors were used for the transfection analyses. Plasmid DNA (1 
µL, 1 mg/mL) was diluted with water (50 µL). The transfection reagent, polyarginine (10 
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μL, 1 mg/mL), polylysine (10 μL, 1 mg/mL), or polyethylenimine (5 μL, 1 mg/mL) was 
diluted with water (50 µL). The two solutions were then vortexed gently and allowed to 
incubate for 20 min at rt, after which they were combined and allowed to incubate for 
another 20 min at rt.  
 
Plasmid DNA (1 µL, 1 mg/mL) was diluted with mTeSR (50 µL). The transfection 
reagent, LPF (2 μL, 1 mg/mL) was diluted with mTeSR (50 µL). The two solutions were 
then vortexed gently and allowed to incubate for 20 min at rt, after which they were 
combined and allowed to incubate for another 20 min at rt. 
 
Various non-viral vectors were used for the transfection analyses. Plasmid DNA (1 
µL, 1 mg/mL) was diluted with mTeSR (50 µL). The transfection reagent, FHD (3.5 μL, 1 
mg/mL) was added to the DNA solution. The solution was then vortexed gently and 
allowed to incubate for 20 min at rt, after which they were combined and allowed to 
incubate for another 20 min at rt. 
 
Solutions of plasmid DNA (5-25 µg/mL) were prepared in water or medium. 
Separately, a solution of 50 µg of the vectors was prepared in 400 µL water. A solution of 
50 µl LPF and FHD in 400 µL media was also prepared as a control. The DNA solution 
was then mixed with the vectors, LPF, or FHD solution and allowed to incubate at room 
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temperature for 20 min. Dynamic light scattering (DLS) and zeta potential analysis were 
conducted on the samples with a Malvern Zetasizer. 
 
4.2.4 hESC Transfection with Y-27632  
hESCs were seeded on Matrigel-coated 24-well plates and cultured in mTeSR 
medium for 24 h. For the full treatment group, Y-27632 was added into the culture medium 
at a final concentration of 0, 10, 30 or 50 µM for 4 h prior to the transfection. 
Nanocomplexes prepared from pEGFP-N1 plasmid and different transfection vectors were 
added dropwise into the media and cells were cultured at 37°C for 4 h. For the pre-treatment 
group, cells were treated with Y-27632 (50 µM) for 4 h at 37°C prior to transfection. The 
cells were then washed with PBS and fresh media was added prior to the addition of the 
nanocomplex and further incubation at 37°C for 4 h. For the post-treatment group, cells 
were treated with Y-27632-free medium for 4 h prior to transfection. Directly prior to 
transfection, the medium was replaced with Y-27632 (50 µM) containing medium, and 
cells were transfected with various vectors at 37°C for 4 h. In all three cases, 4 h after 
treatment with the nanocomplexes, the media was replaced with fresh mTeSR and cultured 
for 48 h before measurement of the transfection efficiency by flow cytometry. 
Alternatively, 10 µM of blebbistatin, a non-muscle myosin IIA inhibitor, downstream of 
the rho-associated protein kinase, was added to the cells prior to and during transfection. 
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4.2.5 Intracellular Uptake Studies 
DNA (1 mg/mL) was labeled with YOYO-1 (20 µM) at one dye molecule per 50bp 
of DNA[11], and was allowed to form nanocomplexes with transfection reagents as 
described above. hESCs were plated on matrigel coated 24-well plate and cultured until 
they reached medium (50 cells) sized colonies. Nanocomplexes were added at 1 µg YOYO-
1-DNA/well and cells were incubated at 37°C for 4 h. Cells were then harvested, re-
suspended in PBS, and subjected to flow cytometry analysis to quantify the cellular uptake 
level of YOYO-1-DNA.  
  
To elucidate the mechanisms underlying the cellular internalization of FHD/DNA 
nanocomplexes, the uptake study was performed at 4 °C or in the presence of various 
endocytic inhibitors. Cells were pre-treated with chlorpromazine (10 µg/mL), genistein 
(200 µg/mL), methyl-β-cyclodextrin (mβCD, 50 µM), dynasore (80 µM), or wortmannin 
(50 nM) for 30 min before addition of the nanocomplexes and throughout the uptake study 
at 37°C for 2 h. Results were expressed as percentage uptake level of control cells that were 
treated with the nanocomplexes at 37 °C for 2 h in the presence of Y-27632 (50 µM) while 
in the absence of endocytic inhibitors. 
 
4.2.6 hESC spreading and transfection analysis 
hESC H1 were plated on matrigel coated 96-well plates as medium sized colonies 
and cultured for 24 h. Y-27632 was added at various concentrations (0, 10, 20, and 50 µM) 
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and after 4 h incubation, the cell nuclei were stained with Hoechst 33258 and the cytoplasm 
was stained with CellTracker Red CMTPX per manufacturer’s protocols. Five wells were 
imaged with 9 fields each using the GE InCell Analyzer 2000 in the Hoechst and Texas 
Red channel (Fig. 4.17). The images were then analyzed using the GE InCell Analyzer 
workstation. The nuclei were identified using top-hat segmentation in the Hoechst channel, 
and the cell area was analyzed and calculated through the analysis in the CMPTX channel 
using multiscale top-hat. The cytoplasmic area was then normalized to the number of nuclei 
counted. 
 
hESC H1 were seeded on matrigel-coated 24-well plates and cultured in mTeSR 
medium for 24 h. Before transfection, Y-27632 was added into the culture medium at a 
final concentration of 0, 10, 30 or 50 µM, and incubated at 37 °C for 4 h. Nanoparticles 
from pEGFP-N1 and FHD were added dropwise into the culture medium and cells were 
further incubated at 37°C for 4 h. The medium was then replaced with fresh mTeSR 
medium, and cells were further cultured for 48 h. After 48 h, the cell nuclei were stained 
with Hoechst 33258. Forty-five fields were imaged using the GE InCell Analyzer 2000 in 
the Hoechst and GFP channel (Fig. 4.18). Using the InCell Analyzer Workstation, the 
nuclei were identified using top-hat segmentation in the Hoechst channel and the numbers 
of cells were then calculated. The identified nuclei were then further segmented by 
multiscale top-hat in the GFP signal to determine the number of cells with positive GFP 
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signals. The transfection efficiency was then determined by dividing the number of GFP 
positive cells by the total number of cells. 
 
4.2.7 siGLO Green Delivery into hESC 
Two wells of a 6 well plate of hESC H1s or WA01 OCT4 GFP KI H1 were plated 
into a 24 well plate coated with Matrigel a day or two before transfection. Y-27632 at 0 
μM, 10 μM or 30 μM was added to the cells 4 hours before transfection. For transfection 
with Lipofectamine 2000 with incubation, siGlo Green (30 picomoles) was added to 
Optimem (50 μL) and Lipofectamine (1 μL, 1 mg/mL) was added to another tube of 
Optimem (50 μL). The two solutions were mixed and incubated at room temperature for 
20 minutes and added directly to the cells. For the alternative method, instead of mixing 
the two solutions, the polymer solution was added directly to the cells first and then the 
solution containing the siGlo Green was added separately to the cells right after. The cells 
were incubated for either 48 hours and collected and analyzed with flow cytometry.  
 
4.2.8 RITC Silica nanoparticle synthesis  
Methanol (1.0 mL), DI water (0.27 mL), and concentrated ammonia (0.24 mL) were 
mixed. TEOS (62.5 μL, 0.28 mmol) was then added to the solvent mixture followed by the 
addition of a DMSO solution (20 μL) of trimethylorthosilicate (2 mg, 4.3 μmol). 
Fabrication of monodisperse RITC-NCs with other sizes can be similarly achieved by 
tuning the concentrations of TEOS, water, and ammonia. After the reaction was complete, 
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without isolating the NCs, a methanol solution of RITC-trimethylorthosilicate (10 mg/mL, 
100 μL) was added to the silica NC solution. The mixture was stirred for 12 h in the dark. 
A methanol solution of mPEG-sil (10 mg/mL, 100 μL) was added. RITC-NCs were 
collected by centrifugation at 15k rpm, washed with ethanol (3 × 1 mL), and redispersed 
in DI water or 1× PBS buffer before use. [12] 
 
4.2.9 hESC RITC-SNP Uptake  
Two wells of a 6 well plate of hESC H1s or WA01 OCT4 GFP KI H1 were plated 
into a 24 well plate coated with Matrigel a day or two before transfection. Y-27632 at 0 
μM or 3 μM was added to the cells 4 hours before transfection. The RITC-SNP (30-40 μg) 
was added to the wells and incubated for 2h. The cells were then washed with PBS (3x) 
and analyzed with flow cytometry. 
 
4.2.10 Sample preparation and flow cytometry analysis 
Prior to analysis by flow cytometry, transfected cells on the 24-well plate were 
washed with PBS (3 × 500 μL) to remove any residual serum, dead cells, and debris. 
Accutase (100 µL) was added to detach the cells from the plate, and PBS (100 µL) was 
then added to re-suspend the cells. An aqueous solution of paraformaldehyde (4%, 100 µL) 
was added to fix the cells, which were then subject to flow cytometry analysis. 
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4.2.11 Cell viability 
 For the MTT assays cytotoxicity assessment, 1 6-well well of confluent hESCs was 
plated into 24 wells of a matrigel coated 48-well plate one day before transfection. The 
cells were then pre-treated for 4 h with 0, 10, 30, and 50 µM of Y-27632 for 4 h and 
transfected with FHD as described previously. The cells were further incubated for 4 h at 
37°C in the transfection mix before removal of the transfection reagent and replacement of 
fresh media. After 48 h, the cell viability was monitored by the MTT assay and was 
represented as percentage viability of control cells that did not receive any transfection 
treatment. For the MTT assay, the cells were washed with PBS and MTT solution was 
added. Following 4-h incubation at 37°C, MTT solubilization solution (10% Triton X-100 
in acidic (0.1M HCl) isopropanol) was added to the cells and the absorbance of 570 nm 
light was quantified on a Perkins Elmer plate reader (Waltham, MA, USA). 
 
4.2.12 Western blot analysis and SSEA-4 staining 
After 72 h, the cells were stained with DAPI (250 µL, 3 nM) and SSEA-4–PE (250 
µL, 0.02 mg/mL), a pluripotency cell marker, for 30 min at 37 °C. The cells were imaged 
using the GE InCell Analyzer 2000.  
 
After 4 d treatment of 50 µM Y-27632 and FHD transfection, the cells were lysed 
with the RIPA buffer, mixed with Laemmli buffer supplemented with 2-Mercaptoethanol, 
and heated at 100 °C for 5 min to denature the proteins. After being cooled in ice, the 
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samples were subjected to electrophoresis on a 10% SDS PAGE Gel at 120 V for 1.5 h, 
and wet transferred to the nitrocellulose membrane using the AMRESCO Rapid Western 
Blot Kit per manufacturer’s instructions. The membrane was stained with OCT4 and α-
Tubulin primary antibodies and then with HRP-tagged secondary.  
 
4.3 Results 
4.3.1 Inhibition of Rho-associated kinase facilitates non-viral gene transfection  
 Prior to the transfection assessment, the pEGFP-N1 plasmid nanocomplexes with 
the gene transfection vectors were evaluated by dynamic light scattering and zetasizer to 
determine their complexation capacities. I confirmed that all tested materials were able to 
form nanocomplexes with DNA, as reported by many other prior studies. Upon 
complexation with DNA, the nanocomplexes of DNA with PLR, PLL and PEI gave sizes 
around 60-70 nm while DNA complexes with LPF and FHD following the standard 
protocol afforded much larger particle size (above 300 nm, Fig. 4.1).  PLR, PLL, and PEI 
are cationic polymers with sufficiently long backbones so that they can well condense the 
anionic DNA into compact nanocomplexes via electrostatic interaction as well as 
intermolecular entanglement. In comparison, LPF and FHD are cationic lipid based 
materials, and their short molecular length would prevent sufficient entanglement with the 
DNA molecules, thus leading to relatively larger complexes.  
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Transfection efficiency of each material was then evaluated in the presence (50 
µM) or absence of Y-27632 by monitoring the EGFP expression, attempting to probe the 
effect of Y-27632 on gene transfection. As shown in Fig. 4.2, PLR was unable to mediate 
transfection in H1 hESCs (transfection efficiency < 1%), which was consistent with 
previous findings in multiple cell lines[13,14]. Upon the treatment of Y-27632, all other 
materials significantly increased their transfection efficiency of hESCs as measured by 
flow cytometry. Specifically, the PLL transfection efficiency with Y-27632 increased from 
3.0 ± 0.8% to 5.8 ± 0.8%. For PEI mediated transfection, the transfection efficiency 
increased from 7.7 ± 0.8% to 13.7 ± 1.3% in the presence of Y-27632. Similar enhancement 
of gene transfection efficiencies was observed with the use of Y-27632 when LPF and FHD 
were used as transfection agents.  Their transfection efficiencies improved from 8.8 ± 0.8% 
to 15.3 ± 1.2% and 21.5 ± 0.9% to 37.0 ± 1.0%, respectively. These studies clearly 
demonstrate that Y-27632 treatment can universally increase the transfection efficiency by 
approximately 1.7 to 1.9 fold in non-viral gene delivery to hESCs.   
 
4.3.2 Y-27632 treatment increases cell spreading 
To further investigate the treatment effect of Y-27632, transfection studies were 
performed on H1 hESC colonies that were treated with varying concentrations of Y-27632 
for 4 h prior to and during transfection. DNA/FHD complexes, which displayed the highest 
transfection efficiency among all tested systems, were selected for further studies. With no 
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treatment, the EGFP transfection efficiency was 14.4 ± 0.9%. With 10 µM treatment of Y-
27632, the transfection efficiency increased to 17.6 ± 1.4%. When the concentration of Y-
27632 was increased to 30 µM and 50 µM, the respective efficiency increased to 22.7 ± 
0.8% and 26.4 ± 1.1% (Fig. 4.3-4.4). To confirm that the mechanism of increased 
transfection efficiency was due to the spreading and actin-myosin interactions, the cells 
were treated with blebbistatin, a small molecule that acts downstream of Y-27632[15], 
inhibits non-muscle myosin IIA, reduces actin/myosin interactions and alters the 
intracellular structure and morphology. Treatment of blebbistatin at 10 µM also resulted in 
increased transfection efficiency of DNA/FHD complex up to 17.8 ± 0.4%, indicating a 
strong correlation between cell structure and transfection efficiency (Fig. 4.3).   
 
When hESC colonies were treated with Y-27632 for 4 h at varying concentrations 
(10, 30, and 50 µM), significant morphological changes of the cells were observed. In the 
absence of Y-27632, the cells maintained a two-dimensional cobble stone like colony 
morphology, and the cells were tight and rounded up (Fig. 4.5). At 10 µM, the colonies 
started to spread and lose their rounded-up structure. At 30 and 50 µM, the cells were even 
more spread out and elongated, further indicating that they had relaxed their original 
structure. This increased the surface area and decreased the surface membrane tension. To 
further validate the Y-27632-mediated cell spreading, the cytoplasm and nuclei of the Y-
27632-treated cells were respectively labelled before cells were imaged and analysed using 
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the GE InCell Analyzer (Fig S4.1). Without Y-27632 treatment, the cells were calculated 
to have a cytoplasmic area of 445 ± 29.8 µm2 per cell. When treated with Y-27632 at 10, 
30, and 50 µM, the cytoplasmic area per cell increased to 516 ± 8.0, 563 ± 32.7 and 589 ± 
18.6 µm2, respectively (Fig. 4.6). The increased cytoplasmic area thus substantiated the 
promotion of cell spreading upon Y-27632 treatment. Through further analysis of the cell 
spreading effect on transfection efficiency, the GFP efficiency was also measured using 
the GE InCell Analyzer and InCell Workstation (Fig S4.2). With the increased spreading, 
the GFP transfection efficiency increases from about 6.3 ± 3.4% at 0 µM to 10.9 ± 4.4%, 
22.8 ± 0.6% and 30.6 ± 1.7% at 10, 30, and 50 µM of Y-27632 treatment, respectively (Fig 
4.6). Through the GE InCell imaging analysis of the hESCs cytoplasmic area and GFP 
expression, correlation between the cell spreading and GFP transfection upon the treatment 
of Y-27632 was noted.  
 
4.3.3 Sequential treatment of Y-27632 and uptake inhibition study  
To study the importance of morphological changes, hESCs were treated with Y-
27632 in three different stages, with FHD as the model vector. When the cells were treated 
with Y-27632 for 4 h and removed before transfection, the transfection efficiency was 
28.9%. When the cells were treated with Y-27632 only during the transfection for 4 h, the 
transfection efficiency decreased to 25.4%. Finally, when the cells were treated for 4 h 
before and during the transfection with Y-27632, the transfection efficiency increased to 
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31.3% (Fig. 4.7). The increase in transfection when the hESCs were pretreated with Y-
27632 indicates the importance of altering the cell morphology before the transfection. 
 
A further uptake study of the YOYO-1-DNA was conducted at various 
concentrations of Y-27632. In the absence of Y-27632, 67% of the cells had taken up the 
FHD/YOYO-1-DNA nanocomplexes. When the concentration of Y-27632 was increased 
from 10 to 50 µM, the uptake level continued to increase to 95%, in consistence with the 
transfection trend (Fig. 4.8). Such observation indicated that Y-27632 promoted the overall 
cellular uptake of the nanocomplexes as a result of facilitated colony spreading, which 
ultimately potentiated the transfection efficiency.  
 
The internalization mechanism is often closely related to the intracellular fate and 
ultimately the transfection efficiency. To this end, the effect of Y-27632 on the intracellular 
kinetics was further probed by monitoring the cell uptake in the presence of different 
endocytic inhibitors. Energy dependent endocytosis was blocked at 4°C; clathrin mediated 
endocytosis was blocked by chlorpromazine by triggering dissociation of the clathrin 
lattice; caveolae was inhibited by genistein and mβCD by inhibiting tyrosine kinase and 
depleting cholesterol, respectively; clathrin mediated endocytosis and caveolae were 
inhibited by dynasore by inhibiting dynamin; macropinocytosis was inhibited by 
wortmannin by inhibiting phosphatidyl inositol-3-phosphate[16,17]. As shown in Fig. 4.9, 
through the different inhibition of endocytotic pathways, the uptake of YOYO-1-DNA did 
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not diminish through the use of the inhibitors. On the other hand, at 4°C, there was a 
decrease in uptake efficiency. This suggests that the FHD nanocomplexes entered the cells 
partially via energy dependent endocytosis, but not through clathrin and caveolae mediated 
endocytosis or macropinocytosis. Interestingly, there was an increase of uptake at 4°C from 
50% to 75% in the Y-27632 treated cells. Potentially, this denotes the decreased energy 
requirement for endocytosis with the treatment of Y-27632. 
 
4.3.4 Combination of Y-27632 treatment with HA coated nanocomplexes 
To demonstrate the combined effect of Y-27632 treatment and HA coated 
DNA/PVBLG-8 nanocomplexes, the two methods were combined in their transfection into 
H1 hESCs. Using the optimal transfection ratios of 1:7.5 (DNA:PVBLG-8 weight ratios) 
and 1:7.5:7.5 (DNA:PVBLG-8:HA weight ratios), the transfection efficiency increases 
from 11.2% to 15.4% GFP positive for PVBLG-8 only transfection with and without Y-
27632 treatment, respectively. Finally, using the HA coated nanocomplexes the 
transfection efficiency increased to 16.8% and 24.5% GFP positive with and without Y-
27632 treatment, respectively. This indicates that coupling the two systems does 
significantly increase the transfection efficiency.  
 
4.3.5 siSRNA siGLO Green uptake 
Transfection of siRNA siGlo Green was performed using Lipofectamine 2000 with 
the treatment of Y-27362 at 0 µM, 10 µM, and 30 µM concentrations with uptake 
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efficiencies of 55.67%, 75.4% and 85.92%, respectively, again demonstrating the effects 
of transfection efficiency enhancement of Y-27632 (Fig. 4.11). 
 
4.3.6 Nanoparticle uptake 
 In the initial study, 3 sizes of silica nanoparticles tagged with RITC  (RITC-SNP) 
were synthesized using the Stober method [12], 200, 51 and 25 nm. Two sets of RITC-SNP 
were synthesized one with and one without PEG surface modifications. These RITC-SNP 
were incubated for 2 h with the cells treated with 0 μM or 30 μM Y-27632. For the 200, 
50, 25 nm sized RITC-SNP with no surface modifications, the transfection efficiencies 
without Y-27632 treatment and incubated for 2 h were 1.75%, 1.23% and 0.65%, 
respectively. The transfection efficiencies for cells treated with 30 μM Y-27632 were 9.5%, 
6.5% and 3.5% (Fig. 4.12). For the 200, 50, 25 nm sized RITC-SNP with no surface 
modifications the transfection efficiencies without Y-27632 treatment and incubated for 5 
h were 70.03%, 86.54% and 86%, respectively. The transfection efficiencies for cells 
treated with 3x Y-27632 were 83.61%, 92.65% and 94.53% (Fig. 4.13). These trends 
demonstrated higher uptake with the treatment or Y-27632 in hESC, especially with the 
use of non-surface modified RITC-SNP. 
 
4.3.7 Treatment of Y-27632 maintains pluripotency of hESCs 
Treatment of hESCs with Y-27632 at the concentration of 50 µM significantly 
increases non-viral transfection efficiency.  The treated cells can also revert back to their 
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normal hESC morphology 48 h post-treatment (Fig. 4.4). This study demonstrates that Y-
27632 only transiently alters the hESC morphology to facilitate improved gene delivery. 
To further confirm whether the hESCs were only transiently altered by the treatment of Y-
27632 and FHD transfection, extracellular stage specific embryonic antigen 4 (SSEA-4) 
was stained with PE conjugated antibodies and imaged 72 h post transfection with 50 µM 
Y-27632 treatment (Fig. 4.14). The cells stained uniformly positive for SSEA-4, indicating 
well-maintained pluripotency.  A western blot assay of the hESCs conducted 4 days post 
FHD/DNA transfection with Y-27632 also indicated unaltered expression of OCT4, a gene 
indicator of hESC pluripotency. With the treatment of Y-27632 at all concentrations, there 
was no change in the OCT4 expression. However, when treated with 10, 30, and 50 µM of 
Y-27632 in the presence of FHD, a slight reduction in the OCT4 expression level was 
observed, indicating that Y-27632 itself did not affect pluripotency and the minor change 
of OCT4 expression could be induced by the transfection reagent.  These experiments 
substantiated that gene transfection and Y-27632 treatment were transient and the cells 
were able to revert back to their natural pluripotent state after removal of Y-27632 (Fig. 
4.15). The treatment of hESCs with Y-27632 also showed no cytotoxicity to the cells at 
any treatment concentrations (Fig. 4.16). The Y-27632 treatment at any of the 
concentrations for transfection demonstrated only transient alteration of the cells with well-
retained pluripotency and low cytotoxicity.   
 
4.4 Discussion 
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In the current study, I demonstrated that with the treatment of Y-27632, transfection 
efficiencies of a variety of non-viral gene delivery materials in hESC, including PLR, PLL, 
PEI, LPF, and FHD, were markedly augmented. Y-27632 allowed the hESC colonies to 
effectively transform their internal mechanical structure by inhibiting the actin-mysoin 
contractility and cell-to-cell adhesion, thus facilitating spreading of the cells. As such, the 
exposed surface area was increased and the membrane tension was decreased, ultimately 
leading to an increase in the internalization level of exogenous genetic materials. Using 
one of the most efficient commercial transfection reagents, FHD, I demonstrated a dose 
dependent effect of Y-27632 small molecule treatment in hESCs. An increase in the Y-
27632 concentration from 0 to 50 µM correlated to a 1-fold increment in the transfection 
efficiency. To ensure that the increased transfection efficiency was due to the actin-myosin 
inhibition effect on the spreading or morphology change of the cells and not the other 
pathways associated with the rho-associated protein kinase pathway, the cells were also 
treated with 10 µM blebbistatin. Blebbistatin acts downstream of the rho-associated protein 
kinase, and directly inhibits non-muscle myosin IIA. This inhibition directly decreases the 
affinity of myosin with actin, indicating that the Y-27632’s role in the cell morphological 
change is responsible for the increased gene transfection. 
 
From the treatment of varying concentrations of Y-27632, the cell’s morphology 
changes from a rounded up structure to an elongated flat morphology and disassociation 
from the colony. This flattening and spreading of the cells increased the cell surface area 
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that was exposed to exogenous nanocomplexes, and thus the nanocomplexes were more 
readily taken up by the cells. A higher Y-27632 concentration resulted in enhanced cell 
spreading and ultimately increased transfection efficiency. The important role of Y-27632 
in increasing cell adhesion and survival also helped the cells to maintain physiological 
functions, thus contributing to the transfection process[1]. In addition, through the 
spreading and elongation of the cells, the cell membrane could have also decreased 
membrane tension, allowing for a higher rate of endocytosis [5,6]. With decreased 
membrane tension, the energy required for endocytosis is lowered [6], which is shown in 
the 4°C FHD nanocomplex uptake experiment, in which the uptake efficiency increased 
with the treatment of Y-27632.  
 
It is important that the cells be transiently altered before transfection, so that the 
spreading of the cells and decrease of the membrane tension could allow for efficient 
nanocomplex uptake. In our detailed study on the adding sequence of Y-27632, pretreated 
cells showed significantly higher transfection efficiency than post-treated cells, indicating 
the importance of morphological change prior to the transfection process. The altered 
morphology primes the cells by increasing the cytoplasmic area and facilitating the uptake 
of the nanocomplexes during transfection. In consistence with our findings that cells in 
smaller colonies afforded higher transfection efficiencies (data not shown), it was further 
demonstrated that Y-27632-mediated cell spreading and larger cell surface area is 
attributed to the decreased surface tension and de-clumping of the cell colonies.  
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Not only does the pre-treatment with Y-27632 enhance DNA plasmid and siRNA 
nanocomplexes, but it also can enhance the uptake of other nanoparticles, like unmodified 
silica nanoparticles at a varying sizes. As expected, there is a correlation between the 
uptake efficiency and nanoparticle size. For smaller nanoparticles (20-25 nm), the higher 
the uptake efficiency, while larger nanoparticles (200 nm) have much lower uptake 
efficiency. When increasing time of incubation of the nanoparticles, there is a drastic 
increase of nanoparticle uptake. Yet in both cases, the treatment of Y-27632 increases does 
significantly increase the uptake efficiency, indicating that the system works for the uptake 
of all kinds of nanoparticles.  
 
I have also demonstrated that the system of transient change of cell morphology 
with the smart and targeting system can overall significantly increase gene transfection 
efficiency. With the treatment of Y-27632 there is an increase in the transfection of 
PVBLG-8 nanocomplexes, but with also increased cytotoxicity (data not shown). Then 
with the further addition of the HA coating, the transfection efficiency is significantly 
increased, indicating that Y-27632 treatment does not affect caveolae and receptor 
mediated endocytosis pathways, indicating that the system can be coupled together. But 
further optimization is required to bring the two systems together effectively to reach the 
optimal transfection efficiency applicable to stem cell engineering applications.  
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As previously reported [7], the use of Y-27632 does not permanently affect the 
pluripotency and hESC cell state. In accordance with this finding, the cells recovered to 
their natural, tight, two-dimensional colony morphology 72 h after removal of Y-27632. 
Expression of SSEA-4 and OCT4 were also observed, suggesting reversible alteration of 
cell physiology and maintenance of cell pluripotency. 
 
4.5 Conclusion 
I studied and adapted a new approach to increase the non-viral gene delivery to 
hESCs by transiently altering the colony structure to increase their susceptibility for uptake 
of nanocomplexes. Treatment of hESCs with Y-27632 prior to and during transfections 
effectively increases cell spreading and decreases cell membrane tension, which increases 
cell uptake and thus potentiates the gene transfection. The hESC colonies were able to 
return to their original morphology and maintain their pluripotency within hours after 
removal of Y-27632. While most of the current studies in non-viral gene delivery focus on 
the material design, this study opens a new window to control gene transfection in hESCs 
on the cellular side. Therefore it provides a promising approach for manipulation of 
pluripotent stem cells through transient gene therapy, overcoming a big hurdle against 
controlling and studying pluripotent stem cell differentiation and development toward 
various biomedical applications. With the increase in the gene transfection efficiency, an 
increase in differentiation efficiency of hESCs can be expected, which would reduce the 
need for enrichment and sorting of desired cells. This new system has also been shown that 
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it can be coupled with the HA targeting nanocomplex system, which can be further 
optimized to bring non-viral gene delivery into hESCs to levels that can be used instead of 
viral systems for stem cell engineering applications. The preliminary findings of the current 
study also unravel the possibility of manipulating the cellular states and properties in future 
designs of intracellular delivery vehicles into hESCs. A lot of stem cell engineering 
research is heavily reliant on viral gene delivery systems, including reprogramming, 
differentiation, gene targeting/editing, and mechanistic studies, but are then limited due to 
safety concerns. But with these advances towards safe and effective non-viral gene 
delivery, these stem cell engineering applications are one step closer to clinical therapies.  
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4.6 Figures 
 
 
Scheme 4.1: Y-27632 enhances the transfection efficiencies of various polyplexes 
or lipoplexes in hESCs via increased membrane exposure through transient 
spreading of the cells. 
  
Without Y-27632 Treatment With Y-27632 Treatment
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Figure 4.1: Size and zeta potential of various nanocomplexes (w:w): PLR (1:10), 
PLL (1:10), PEI (1:5), LPF (1:2), and FHD (1:3.5) 
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Figure 4.2: Transfection efficiencies of various reagents in hESCs in the presence 
of absence of Y-27632 (50 μM). Cells were pre-treated with Y-27632 cells for 4 h 
before removal of Y-27632 and addition of various complexes. 
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Figure 4.3: Transfection scheme and transfection efficiencies of Fugene HD/DNA 
complexes in H1 hESCs in the presence of Y-27632 or Blebbistatin at various 
concentrations. (* p <0.05, ** p<0.01) 
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Figure 4.4: Fluorescence images of H1 hESCs 48 h post transfection with 
FHD/pEGFP complexes. Cells were pre-treated with 0 µM, 10 µM, 30 µM, and 50 
µM Y-27632 for 4 h before transfection and during the 48-h post incubation. Scale 
bar: 250 µm 
0 µM 10 µM 50 µM30 µM
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Figure 4.5: Bright-field imaging showing the morphological change of hESCs after 
4-h treatment with Y-27632 at various concentrations. Scale bar: 250 µm 
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Figure 4.6: Alteration of the cytoplasm area (unit) per nucleus of hESCs following 
treatment with Y-27632 of various concentrations. Images were taken and 
analyzed with the GE InCell Analyzer. (n=5) 
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Figure 4.7: Transfection efficiency of FHD in hESCs in the presence of Y-27632. 
Y-27632 was applied to the cells for 4 h before transfection, during the 48-h 
transfection period, or a combination thereof. 
  
EGFP Transfection Efficiency Dependence on the Presence 
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Figure 4.8: Cell uptake level of FHD/YOYO-1-DNA complexes in hESCs in the 
presence of various concentrations of Y-27632 (n =3). (* p <0.05, ** p<0.01) 
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Figure 4.9: Cell uptake mechanisms of FHD/YOYO-1-DNA complexes in hESCs 
in the presence or absence of Y-27632. Results were expressed as percent 
uptake level of control cells without low temperature (4 oC) or endocytic inhibitor 
treatment (n=3). 
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Figure 4.10: Transfection efficiencies of PVBLG-8 (1:7.5 DNA:PVBLG-8 w:w ratio)  
and HA coated DNA/PVBLG-8 nanocomplexes (1:7.5:7.5 DNA:PVBLG-8:HA 
w:w:w ratio) in hESCs in the presence of absence of Y-27632 (50 μM). Cells were 
pre-treated with Y-27632 cells for 4 h before removal of Y-27632 and addition 
nanocomplexes. 
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Figure 4.11: Flow Cytometry of siGlo Green (siRNA analog) using Lipofectamine, 
after 3 h Y-27632 incubation. 
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Figure 4.12: Flow Cytometry data analysis of hESC with and without treatment of 
Y-27632 with different sizes of SNP tagged with RITC without surface modification 
after 2 h incubation. 
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Figure 4.13: Flow Cytometry data analysis of hESC with and without treatment of 
Y-27632 with different sizes of SNP tagged with RITC without surface modification 
after 5 h incubation. 
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Figure 4.14: Y-27632 does not compromise the pluripotency of hESCs. DAPI and 
SSEA4 staining patterns of hESCs without Y-27632 treatment (control group) or 
transfected with FHD in the presence of 50 µM Y-27632 (FHD group). Scale bar: 
250 µm 
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Figure 4.15: Western blot analysis on the OCT4 expression in hESCs 5 days post 
FHD transfection and treatment of Y-27632 at various concentrations. 
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Figure 4.16: Cytotoxicity of H1 hESCs 48 h after transfection with FHD at various 
concentrations MTT cell viability assay of the FHD transfection with varying 
concentrations (0-50 µM) of Y-27632 treatment in H1 hESCs after 48 h. 
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Figure 4.17: Representative images of the alteration of the hESC cytoplasmic area 
following treatment with Y-27632 of various concentrations (0, 10, 30 and 50 µM). 
First row represents the Hoechst channel and the second row represents CMTPX 
cell tracking channel. The third row represent the software generated 
segmentation used for analysis. The blue outline represents the identified nuclei 
and the green outline is the identified CMTPX stain of the cellular cytoplasm from 
which the cell area was calculated. 
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Figure 4.18: Representative images of the transfection of hESCs after alteration 
of the cytoplasm area with the treatment of Y-27632 at various concentrations (0, 
10, 30 and 50 µM). First row represents the Hoechst channel and the second row 
represents the GFP channel. The third row represent the software generated 
segmentation used for analysis. Blue outline represents the identified nuclei and 
green outline is the determined cell cytoplasm as extrapolated by the nuclei and 
GFP channel.  
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